




Leukemia




Non-Small Cell Lung Cancer




Colon Cancer




CNS Cancer




Melanoma




Ovarian Cancer




Renal Cancer



Prostate Cancer



Breast Cancer



National Cancer Institute Developmental Therapeutics Program
In-Vitro Testing Results

NSC : D - 815555 / 1	Experiment ID : 1908NS46	Test Type : 08	Units : Molar
Report Date : October 08, 2019	Test Date : August 05, 2019	QNS :	MC :
COMI : KA1A	Stain Reagent : SRB Dual-Pass Related	SSPL : 0X0S	

Panel/Cell Line	Log10 Concentration														
	Time Zero	Ctrl	-8.0	-7.0	-6.0	-5.0	-4.0	-8.0	-7.0	-6.0	-5.0	-4.0	GI50	TGI	LC50
Leukemia															
CCRF-CEM	0.427	2.554	2.557	2.530	2.015	0.455	0.376	100	99	75	1	-12	2.17E-6	1.25E-5	> 1.00E-4
HL-60(TB)	0.581	2.417	2.217	2.210	1.767	0.473	0.564	89	89	65	-19	-3	1.50E-6	5.97E-6	> 1.00E-4
K-562	0.163	1.719	1.620	1.743	1.254	0.172	0.194	94	102	70	1	2	1.94E-6	> 1.00E-4	> 1.00E-4
MOLT-4	0.558	2.737	2.680	2.616	2.186	0.581	0.477	97	94	75	1	-15	2.17E-6	1.16E-5	> 1.00E-4
SRPMI-8226	0.652	2.516	2.503	2.492	1.973	0.360	0.349	99	99	71	-45	-46	1.52E-6	4.10E-6	> 1.00E-4
SP	0.160	0.537	0.509	0.499	0.393	0.170	0.147	93	90	62	3	-8	1.57E-6	1.76E-5	> 1.00E-4
Non-Small Cell Lung Cancer															
A549/ATCC	0.458	2.393	2.334	2.363	2.098	0.508	0.306	97	98	85	3	-33	2.65E-6	1.18E-5	> 1.00E-4
EKVX	0.760	2.034	1.910	1.970	1.784	0.420	0.056	90	95	80	-45	-93	1.75E-6	4.39E-6	1.29E-5
HOP-62	0.858	2.356	2.199	2.371	2.433	0.354	0.037	90	101	105	-59	-96	2.17E-6	4.38E-6	8.84E-6
HOP-92	1.121	1.808	1.687	1.745	1.593	0.483	0.080	82	91	69	-57	-93	1.41E-6	3.52E-6	8.81E-6
NCI-H226	1.223	2.044	1.977	1.966	1.955	0.974	0.500	92	90	89	-20	-59	2.28E-6	6.51E-6	5.81E-5
NCI-H23	0.626	2.175	2.122	2.115	1.955	0.273	0.175	97	96	86	-56	-72	1.79E-6	4.01E-6	9.01E-6
NCI-H322M	0.737	2.180	2.112	2.154	1.961	0.171	0.008	95	98	85	-77	-99	1.64E-6	3.35E-6	6.82E-6
NCI-H460	0.299	2.841	2.832	2.814	2.222	0.187	0.135	100	99	76	-38	-55	1.68E-6	4.65E-6	5.15E-5
NCI-H522	0.971	2.414	2.376	2.329	2.279	0.300	0.068	97	94	91	-69	-93	1.80E-6	3.69E-6	7.59E-6
Colon Cancer															
COLO 205	0.587	2.701	2.613	2.764	2.760	0.193	0.124	96	103	103	-67	-79	2.05E-6	4.03E-6	7.93E-6
HCC-2998	0.841	2.742	2.684	2.646	2.558	0.125	0.129	97	95	90	-85	-85	1.70E-6	3.27E-6	6.30E-6
HCT-116	0.217	2.234	2.144	2.211	1.617	0.041	0.001	96	99	69	-81	-100	1.35E-6	2.89E-6	6.21E-6
HCT-15	0.353	1.719	1.593	1.596	1.274	0.306	0.134	91	91	67	-13	-62	1.64E-6	6.84E-6	5.66E-5
HT29	0.309	2.331	2.322	2.362	2.317	0.369	0.200	100	102	99	3	-35	3.25E-6	1.19E-5	> 1.00E-4
KM12	0.398	2.522	2.404	2.537	2.253	0.428	0.271	94	101	87	1	-32	2.72E-6	1.10E-5	> 1.00E-4
SW-620	0.295	2.387	2.238	2.200	2.069	0.184	0.122	93	91	85	-38	-59	1.92E-6	4.93E-6	3.88E-5
CNS Cancer															
SF-268	1.211	2.867	2.792	2.780	2.619	0.980	0.633	95	95	85	-19	-48	2.17E-6	6.55E-6	> 1.00E-4
SF-539	0.856	2.968	2.873	2.878	2.743	0.028	0.014	95	96	89	-97	-98	1.63E-6	3.02E-6	5.61E-6
SNB-19	0.515	2.107	2.062	2.075	1.883	0.114	0.020	97	98	86	-78	-96	1.66E-6	3.34E-6	6.75E-6
SNB-75	0.986	1.654	1.493	1.484	1.401	0.091	0.021	76	75	62	-91	-98	1.20E-6	2.55E-6	5.41E-6
U251	0.395	2.106	1.954	2.001	1.826	0.026	0.010	91	94	84	-94	-97	1.55E-6	2.97E-6	5.68E-6
Melanoma															
LOX IMVI	0.564	3.058	2.953	2.948	2.750	0.059	0.058	96	96	88	-90	-90	1.63E-6	3.12E-6	5.98E-6
MALME-3M	0.780	1.920	1.732	1.866	1.785	0.088	0.020	84	95	88	-89	-97	1.64E-6	3.15E-6	6.04E-6
M14	0.542	2.280	2.216	2.258	2.104	0.168	0.041	96	99	90	-69	-93	1.78E-6	3.68E-6	7.58E-6
MDA-MB-435	0.476	2.280	2.311	2.272	2.067	0.352	0.030	102	100	88	-26	-94	2.16E-6	5.90E-6	2.25E-5
SK-MEL-2	1.142	2.147	2.127	2.242	2.280	0.490	0.181	98	110	113	-57	-84	2.35E-6	4.62E-6	9.08E-6
SK-MEL-28	0.742	2.239	2.329	2.302	2.209	0.171	0.026	106	104	98	-77	-97	1.88E-6	3.63E-6	7.01E-6
SK-MEL-5	1.186	3.252	3.260	3.209	3.160	0.016	0.013	100	98	96	-99	-99	1.72E-6	3.10E-6	5.61E-6
UACC-257	1.038	2.576	2.415	2.532	2.277	0.331	0.079	89	97	81	-68	-92	1.61E-6	3.48E-6	7.55E-6
UACC-62	0.777	2.958	2.804	2.851	2.678	0.290	0.028	93	95	87	-63	-96	1.77E-6	3.82E-6	8.23E-6
Ovarian Cancer															
IGROV1	0.647	2.383	2.356	2.441	2.278	0.327	0.122	98	103	94	-49	-81	2.03E-6	4.52E-6	1.04E-5
OVCAR-3	0.467	1.870	1.914	1.936	1.662	0.111	0.043	103	105	85	-76	-91	1.65E-6	3.37E-6	6.87E-6
OVCAR-4	0.550	1.330	1.270	1.299	1.129	0.609	0.078	92	96	74	8	-86	2.30E-6	1.20E-5	4.13E-5
OVCAR-5	0.688	1.494	1.422	1.467	1.413	0.402	0.109	91	97	90	-42	-84	2.01E-6	4.83E-6	1.58E-5
OVCAR-8	0.486	2.477	2.453	2.435	1.976	0.336	0.136	99	98	75	-31	-72	1.72E-6	5.10E-6	2.91E-5
NCI/ADR-RES	0.606	2.024	1.904	1.970	1.740	0.452	0.273	92	96	80	-25	-55	1.92E-6	5.73E-6	6.75E-5
SK-OV-3	1.198	2.385	2.344	2.542	2.443	0.700	0.056	97	113	105	-42	-95	2.37E-6	5.20E-6	1.43E-5
Renal Cancer															
786-0	0.861	2.665	2.521	2.656	2.561	0.023	0.017	92	99	94	-97	-98	1.70E-6	3.10E-6	5.66E-6
A498	1.701	2.617	2.435	2.497	2.396	0.131	0.052	80	87	76	-92	-97	1.42E-6	2.83E-6	5.60E-6
ACHN	0.410	1.693	1.714	1.760	1.552	0.118	-0.002	102	105	89	-71	-100	1.75E-6	3.59E-6	7.36E-6
CAKI-1	0.452	1.446	1.333	1.344	1.168	0.203	-0.002	89	90	72	-55	-100	1.49E-6	3.68E-6	9.12E-6
RXF 393	1.217	1.954	1.873	1.955	1.806	0.114	0.081	89	100	80	-91	-93	1.50E-6	2.94E-6	5.78E-6
SN12C	0.632	2.663	2.589	2.641	2.410	0.526	0.208	96	99	88	-17	-67	2.29E-6	6.91E-6	4.57E-5
TK-10	0.857	1.784	1.666	1.656	1.903	0.618	0.064	87	86	113	-28	-93	2.79E-6	6.34E-6	2.20E-5
UO-31	0.517	1.884	1.781	1.778	1.656	0.011	0.023	92	92	83	-98	-96	1.53E-6	2.88E-6	5.44E-6
Prostate Cancer															
PC-3	0.576	2.279	2.171	2.206	1.966	0.173	0.063	94	96	82	-70	-89	1.62E-6	3.45E-6	7.38E-6
DU-145	0.449	2.051	1.996	2.067	1.772	0.140	0.037	97	101	83	-69	-92	1.64E-6	3.51E-6	7.50E-6
Breast Cancer															
MCF7	0.554	2.479	2.241	2.223	1.733	0.508	0.211	88	87	61	-8	-62	1.45E-6	7.60E-6	5.99E-5
MDA-MB-231/ATCC	0.717	1.840	1.725	1.779	1.709	0.797	0.335	90	95	88	7	-53	2.96E-6	1.31E-5	8.80E-5
HS 578T	1.498	2.703	2.621	2.674	2.478	1.341	1.212	93	98	81	-11	-19	2.19E-6	7.68E-6	> 1.00E-4
BT-549	0.946	2.499	2.311	2.450	2.091	0.103	0.026	88	97	74	-89	-97	1.40E-6	2.84E-6	5.75E-6
MDA-MB-468	1.011	2.114	1.972	2.019	1.952	0.351	0.356	87	91	85	-65	-65	1.72E-6	3.68E-6	7.91E-6

National Cancer Institute Developmental Therapeutics Program		NSC : D - 815555/1	Units :Molar	SSPL :0X0S	EXP. ID :1908NS46	
Mean Graphs		Report Date :October 08, 2019		Test Date :August 05, 2019		
Panel/Cell Line	Log ₁₀ GI50	GI50	Log ₁₀ TGI	TGI	Log ₁₀ LC50	LC50
Leukemia						
CCRF-CEM	-5.66		-4.90		> -4.00	
HL-60(TB)	-5.82		-5.22		> -4.00	
K-562	-5.71		> -4.00		> -4.00	
MOLT-4	-5.66		-4.93		> -4.00	
RPMI-8226	-5.82		-5.39		> -4.00	
SR	-5.80		-4.75		> -4.00	
Non-Small Cell Lung Cancer						
A549/ATCC	-5.58		-4.93		> -4.00	
EKVX	-5.76		-5.36		-4.89	
HOP-62	-5.66		-5.36		-5.05	
HOP-92	-5.85		-5.45		-5.06	
NCI-H226	-5.64		-5.19		-4.24	
NCI-H23	-5.75		-5.40		-5.05	
NCI-H322M	-5.78		-5.48		-5.17	
NCI-H460	-5.77		-5.33		-4.29	
NCI-H522	-5.75		-5.43		-5.12	
Colon Cancer						
COLO 205	-5.69		-5.40		-5.10	
HCC-2998	-5.77		-5.49		-5.20	
HCT-116	-5.87		-5.54		-5.21	
HCT-15	-5.78		-5.16		-4.25	
HT29	-5.49		-4.92		> -4.00	
KM12	-5.57		-4.96		> -4.00	
SW-620	-5.72		-5.31		-4.41	
CNS Cancer						
SF-268	-5.66		-5.18		> -4.00	
SF-539	-5.79		-5.52		-5.25	
SNB-19	-5.78		-5.48		-5.17	
SNB-75	-5.92		-5.59		-5.27	
U251	-5.81		-5.53		-5.25	
Melanoma						
LOX IMVI	-5.79		-5.51		-5.22	
MALME-3M	-5.78		-5.50		-5.22	
M14	-5.75		-5.43		-5.12	
MDA-MB-435	-5.67		-5.23		-4.65	
SK-MEL-2	-5.63		-5.34		-5.04	
SK-MEL-28	-5.73		-5.44		-5.15	
SK-MEL-5	-5.77		-5.51		-5.25	
UACC-257	-5.79		-5.46		-5.12	
UACC-62	-5.75		-5.42		-5.08	
Ovarian Cancer						
IGROV1	-5.69		-5.34		-4.98	
OVCAR-3	-5.78		-5.47		-5.16	
OVCAR-4	-5.64		-4.92		-4.38	
OVCAR-5	-5.70		-5.32		-4.80	
OVCAR-8	-5.77		-5.29		-4.54	
NCI/ADR-RES	-5.72		-5.24		-4.17	
SK-OV-3	-5.63		-5.28		-4.84	
Renal Cancer						
786-0	-5.77		-5.51		-5.25	
A498	-5.85		-5.55		-5.25	
ACHN	-5.76		-5.44		-5.13	
CAKI-1	-5.83		-5.43		-5.04	
RXF 393	-5.82		-5.53		-5.24	
SN12C	-5.64		-5.16		-4.34	
TK-10	-5.55		-5.20		-4.66	
UO-31	-5.82		-5.54		-5.26	
Prostate Cancer						
PC-3	-5.79		-5.46		-5.13	
DU-145	-5.79		-5.46		-5.12	
Breast Cancer						
MCF7	-5.84		-5.12		-4.22	
MDA-MB-23						


Dose Response Curves

Report Date:October 08, 2019

Test Date:August 05, 2019










All Cell Lines

Percentage Growth



S815555

Log₁₀ of Sample Concentration (Molar)



National Cancer Institute Developmental Therapeutics Program
In-Vitro Testing Results

NSC : D - 815556 / 1			Experiment ID : 1908NS46					Test Type : 08			Units : Molar				
Report Date : October 08, 2019			Test Date : August 05, 2019					QNS :			MC :				
COMI : KA2A			Stain Reagent : SRB Dual-Pass Related					SSPL : 0X0S							
Log10 Concentration															
Panel/Cell Line	Time Zero	Ctrl	-8.0	-7.0	-6.0	-5.0	-4.0	-8.0	-7.0	-6.0	-5.0	-4.0	GI50	TGI	LC50
Leukemia															
CCRF-CEM	0.427	2.554	2.624	2.586	1.781	0.462	0.457	103	101	64	2	1	1.66E-6	> 1.00E-4	> 1.00E-4
HL-60(TB)	0.581	2.417	2.423	2.416	1.694	0.562	0.556	100	100	61	-3	-4	1.47E-6	8.86E-6	> 1.00E-4
K-562	0.163	1.719	1.850	1.783	1.257	0.198	0.187	108	104	70	2	2	1.99E-6	> 1.00E-4	> 1.00E-4
MOLT-4	0.558	2.737	2.839	2.758	1.960	0.598	0.515	105	101	64	2	-8	1.70E-6	1.55E-5	> 1.00E-4
SRPMI-8226	0.652	2.516	2.621	2.635	2.058	0.391	0.385	106	106	75	-40	-41	1.66E-6	4.50E-6	> 1.00E-4
SPR	0.160	0.537	0.543	0.541	0.424	0.198	0.167	101	101	70	10	2	2.15E-6	> 1.00E-4	> 1.00E-4
Non-Small Cell Lung Cancer															
A549/ATCC	0.458	2.393	2.313	2.185	2.021	0.459	0.431	96	89	81	.	-6	2.40E-6	1.01E-5	> 1.00E-4
EKVX	0.760	2.034	1.975	1.810	1.729	0.074	0.097	95	82	76	-90	-87	1.43E-6	2.87E-6	5.73E-6
HOP-62	0.858	2.356	2.177	2.101	2.176	0.188	0.131	88	83	88	-78	-85	1.69E-6	3.39E-6	6.77E-6
HOP-92	1.121	1.808	1.723	1.703	1.589	0.210	0.207	88	85	68	-81	-82	1.32E-6	2.86E-6	6.18E-6
NCI-H226	1.223	2.044	1.987	1.907	1.912	0.782	0.706	93	83	84	-36	-42	1.92E-6	5.01E-6	> 1.00E-4
NCI-H23	0.626	2.175	2.132	2.126	1.986	0.234	0.217	97	97	88	-63	-65	1.78E-6	3.83E-6	8.24E-6
NCI-H322M	0.737	2.180	2.071	1.957	1.843	0.008	0.010	92	85	77	-99	-99	1.42E-6	2.73E-6	5.26E-6
NCI-H460	0.299	2.841	2.946	2.824	2.431	0.155	0.102	104	99	84	-48	-66	1.80E-6	4.31E-6	1.24E-5
NCI-H522	0.971	2.414	2.208	2.286	2.029	0.309	0.313	86	91	73	-68	-68	1.46E-6	3.30E-6	7.44E-6
Colon Cancer															
COLO 205	0.587	2.701	2.625	2.615	2.643	0.167	0.113	96	96	97	-72	-81	1.91E-6	3.77E-6	7.45E-6
HCC-2998	0.841	2.742	2.623	2.549	2.509	0.182	0.111	94	90	88	-78	-87	1.69E-6	3.37E-6	6.74E-6
HCT-116	0.217	2.234	2.253	2.087	1.500	0.024	0.009	101	93	64	-89	-96	1.23E-6	2.61E-6	5.54E-6
HCT-15	0.353	1.719	1.666	1.618	1.298	0.197	0.187	96	93	69	-44	-47	1.47E-6	4.07E-6	> 1.00E-4
HT29	0.309	2.331	2.291	2.153	1.882	0.309	0.314	98	91	78	.	.	2.27E-6	.	> 1.00E-4
KM12	0.398	2.522	2.547	2.542	2.326	0.268	0.307	101	101	91	-33	-23	2.14E-6	5.44E-6	> 1.00E-4
SW-620	0.295	2.387	2.433	2.336	2.159	0.141	0.088	102	98	89	-52	-70	1.89E-6	4.26E-6	9.62E-6
CNS Cancer															
SF-268	1.211	2.867	2.729	2.716	2.617	0.821	0.767	92	91	85	-32	-37	1.99E-6	5.31E-6	> 1.00E-4
SF-539	0.856	2.968	2.877	2.817	2.591	0.018	0.012	96	93	82	-98	-99	1.51E-6	2.86E-6	5.42E-6
SNB-19	0.515	2.107	2.029	2.043	1.872	0.045	0.028	95	96	85	-91	-95	1.58E-6	3.04E-6	5.84E-6
SNB-75	0.986	1.654	1.495	1.408	1.361	0.026	0.021	76	63	56	-97	-98	1.10E-6	2.32E-6	4.91E-6
U251	0.395	2.106	2.034	2.005	1.785	0.042	0.028	96	94	81	-89	-93	1.52E-6	2.99E-6	5.87E-6
Melanoma															
LOX IMVI	0.564	3.058	2.984	2.956	2.742	0.024	0.021	97	96	87	-96	-96	1.60E-6	3.00E-6	5.62E-6
MALME-3M	0.780	1.920	1.782	1.708	1.712	0.028	0.017	88	81	82	-96	-98	1.51E-6	2.88E-6	5.49E-6
M14	0.542	2.280	2.217	2.234	2.045	0.105	0.084	96	97	86	-81	-85	1.65E-6	3.29E-6	6.55E-6
MDA-MB-435	0.476	2.280	2.241	2.226	2.010	0.137	0.107	98	97	85	-71	-78	1.68E-6	3.50E-6	7.31E-6
SK-MEL-2	1.142	2.147	2.070	2.193	2.058	0.356	0.401	92	105	91	-69	-65	1.81E-6	3.71E-6	7.63E-6
SK-MEL-28	0.742	2.239	2.259	2.156	2.191	0.100	0.088	101	94	97	-87	-88	1.80E-6	3.37E-6	6.32E-6
SK-MEL-5	1.186	3.252	3.244	3.243	3.135	0.017	0.018	100	100	94	-99	-99	1.70E-6	3.08E-6	5.60E-6
UACC-257	1.038	2.576	2.453	2.376	2.241	0.342	0.236	92	87	78	-67	-77	1.56E-6	3.45E-6	7.63E-6
UACC-62	0.777	2.958	2.781	2.722	2.405	0.047	0.064	92	89	75	-94	-92	1.40E-6	2.77E-6	5.49E-6
Ovarian Cancer															
IGROV1	0.647	2.383	2.309	2.275	2.141	0.157	0.189	96	94	86	-76	-71	1.67E-6	3.40E-6	6.93E-6
OVCAR-3	0.467	1.870	1.857	1.792	1.660	0.090	0.077	99	94	85	-81	-84	1.63E-6	3.26E-6	6.53E-6
OVCAR-4	0.550	1.330	1.315	1.285	1.144	0.019	0.062	98	94	76	-97	-89	1.42E-6	2.76E-6	5.37E-6
OVCAR-5	0.688	1.494	1.434	1.290	1.335	0.190	0.145	93	75	80	-72	-79	1.58E-6	3.35E-6	7.13E-6
OVCAR-8	0.486	2.477	2.400	2.294	1.618	0.112	0.152	96	91	57	-77	-69	1.13E-6	2.66E-6	6.29E-6
NCI/ADR-RES	0.606	2.024	1.967	1.894	1.712	0.397	0.374	96	91	78	-35	-38	1.77E-6	4.93E-6	> 1.00E-4
SK-OV-3	1.198	2.385	2.388	2.284	2.286	0.429	0.547	100	92	92	-64	-54	1.85E-6	3.87E-6	8.11E-6
Renal Cancer															
786-0	0.861	2.665	2.600	2.595	2.586	0.037	0.024	96	96	96	-96	-97	1.73E-6	3.16E-6	5.77E-6
A498	1.701	2.617	2.474	2.407	2.322	0.081	0.090	84	77	68	-95	-95	1.28E-6	2.60E-6	5.28E-6
ACHN	0.410	1.693	1.682	1.664	1.587	0.003	0.002	99	98	92	-99	-100	1.65E-6	3.02E-6	5.52E-6
CAKI-1	0.452	1.446	1.318	1.317	1.099	0.015	0.007	87	87	65	-97	-98	1.24E-6	2.52E-6	5.14E-6
RXF 393	1.217	1.954	1.946	1.884	1.673	0.124	0.111	99	90	62	-90	-91	1.20E-6	2.56E-6	5.46E-6
SN12C	0.632	2.663	2.539	2.469	2.259	0.153	0.102	94	90	80	-76	-84	1.56E-6	3.26E-6	6.83E-6
TK-10	0.857	1.784	1.703	1.698	1.819	0.119	0.148	91	91	104	-86	-83	1.92E-6	3.52E-6	6.45E-6
UO-31	0.517	1.884	1.770	1.669	1.445	0.008	0.005	92	84	68	-99	-99	1.28E-6	2.56E-6	5.11E-6
Prostate Cancer															
PC-3	0.576	2.279	2.188	2.156	1.833	0.045	0.024	95	93	74	-92	-96	1.39E-6	2.78E-6	5.57E-6
DU-145	0.449	2.051	2.043	2.040	1.867	0.072	0.058	100	99	89	-84	-87	1.67E-6	3.26E-6	6.35E-6
Breast Cancer															
MCF7	0.554	2.479	2.327	2.250	1.775	0.328	0.324	92	88	63	-41	-42	1.34E-6	4.05E-6	> 1.00E-4
MDA-MB-231/ATCC	0.717	1.840	1.806	1.676	1.709	0.352	0.293	97	85	88	-51	-59	1.88E-6	4.30E-6	9.84E-6
HS 578T	1.498	2.703	2.631	2.575	2.406	1.312	1.272	94	89	75	-12	-15	1.94E-6	7.22E-6	> 1.00E-4
BT-549	0.946	2.499	2.403	2.382	2.053	0.053	0.036	94	92	71	-94	-96	1.34E-6	2.69E-6	5.39E-6
MDA-MB-468	1.011	2.114	1.996	1.950	1.971	0.261	0.188	89	85	87	-74	-81	1.70E-6	3.47E-6	7.08E-6

National Cancer Institute Developmental Therapeutics Program		NSC : D - 815556/1	Units :Molar	SSPL :0X0S	EXP. ID :1908NS46	
Mean Graphs		Report Date :October 08, 2019		Test Date :August 05, 2019		
Panel/Cell Line	Log ₁₀ GI50	GI50	Log ₁₀ TGI	TGI	Log ₁₀ LC50	LC50
Leukemia						
CCRF-CEM	-5.78		> -4.00		> -4.00	
HL-60(TB)	-5.83		-5.05		-4.00	
K-562	-5.70		> -4.00		-4.00	
MOLT-4	-5.77		-4.81		-4.00	
RPMI-8226	-5.78		-5.35		-4.00	
SR	-5.67		> -4.00		-4.00	
Non-Small Cell Lung Cancer						
A549/ATCC	-5.62		-5.00		> -4.00	
EKVX	-5.84		-5.54		-5.24	
HOP-62	-5.77		-5.47		-5.17	
HOP-92	-5.88		-5.54		-5.21	
NCI-H226	-5.72		-5.30		> -4.00	
NCI-H23	-5.75		-5.42		-5.08	
NCI-H322M	-5.85		-5.56		-5.28	
NCI-H460	-5.74		-5.37		-4.91	
NCI-H522	-5.84		-5.48		-5.13	
Colon Cancer						
COLO 205	-5.72		-5.42		-5.13	
HCC-2998	-5.77		-5.47		-5.17	
HCT-116	-5.91		-5.58		-5.26	
HCT-15	-5.83		-5.39		> -4.00	
HT29	-5.64				> -4.00	
KM12	-5.67		-5.26		> -4.00	
SW-620	-5.72		-5.37		-5.02	
CNS Cancer						
SF-268	-5.70		-5.28		> -4.00	
SF-539	-5.82		-5.54		-5.27	
SNB-19	-5.80		-5.52		-5.23	
SNB-75	-5.96		-5.63		-5.31	
U251	-5.82		-5.52		-5.23	
Melanoma						
LOX IMVI	-5.80		-5.52		-5.25	
MALME-3M	-5.82		-5.54		-5.26	
M14	-5.78		-5.48		-5.18	
MDA-MB-435	-5.78		-5.46		-5.14	
SK-MEL-2	-5.74		-5.43		-5.12	
SK-MEL-28	-5.74		-5.47		-5.20	
SK-MEL-5	-5.77		-5.51		-5.25	
UACC-257	-5.81		-5.46		-5.12	
UACC-62	-5.85		-5.56		-5.26	
Ovarian Cancer						
IGROV1	-5.78		-5.47		-5.16	
OVCAR-3	-5.79		-5.49		-5.19	
OVCAR-4	-5.85		-5.56		-5.27	
OVCAR-5	-5.80		-5.47		-5.15	
OVCAR-8	-5.95		-5.58		-5.20	
NCI/ADR-RES	-5.75		-5.31		> -4.00	
SK-OV-3	-5.73		-5.41		-5.09	
Renal Cancer						
786-0	-5.76		-5.50		-5.24	
A498	-5.89		-5.58		-5.28	
ACHN	-5.78		-5.52		-5.26	
CAKI-1	-5.91		-5.60		-5.29	
RXF 393	-5.92		-5.59		-5.26	
SN12C	-5.81		-5.49		-5.17	
TK-10	-5.72		-5.45		-5.19	
UO-31	-5.89		-5.59		-5.29	
Prostate Cancer						
PC-3	-5.86		-5.56		-5.25	
DU-145	-5.78		-5.49		-5.20	
Breast Cancer						
MCF7	-5.87		-5.39			


Dose Response Curves

Report Date:October 08, 2019

Test Date:August 05, 2019

All Cell Lines


Percentage Growth




S815556

Log₁₀ of Sample Concentration (Molar)


Leukemia




Non-Small Cell Lung Cancer




Colon Cancer




CNS Cancer




Melanoma




Ovarian Cancer




Renal Cancer



Prostate Cancer



Breast Cancer



National Cancer Institute Developmental Therapeutics Program
In-Vitro Testing Results

NSC : D - 815557 / 1			Experiment ID : 1908NS46					Test Type : 08			Units : Molar				
Report Date : October 09, 2019			Test Date : August 05, 2019					QNS :			MC :				
COMI : KA1B			Stain Reagent : SRB Dual-Pass Related					SSPL : 0X0S							
Log10 Concentration															
Panel/Cell Line	Time Zero	Ctrl	-8.0	-7.0	-6.0	-5.0	-4.0	-8.0	-7.0	-6.0	-5.0	-4.0	GI50	TGI	LC50
Leukemia															
CCRF-CEM	0.427	2.555	2.607	2.608	1.682	0.488	0.506	102	102	59	3	4	1.45E-6	> 1.00E-4	> 1.00E-4
HL-60(TB)	0.581	2.330	2.135	2.107	1.465	0.562	0.579	89	87	51	-3	.	1.02E-6	8.66E-6	> 1.00E-4
K-562	0.163	1.677	1.677	1.584	1.037	0.226	0.252	100	94	58	4	6	1.39E-6	> 1.00E-4	> 1.00E-4
MOLT-4	0.558	2.598	2.705	2.592	1.671	0.653	0.628	105	100	55	5	3	1.23E-6	> 1.00E-4	> 1.00E-4
SPMI-8226	0.652	2.496	2.563	2.591	1.826	0.599	0.601	104	105	64	-8	-8	1.55E-6	7.69E-6	> 1.00E-4
SR	0.160	0.499	0.497	0.491	0.393	0.187	0.214	99	98	69	8	16	2.03E-6	> 1.00E-4	> 1.00E-4
Non-Small Cell Lung Cancer															
A549/ATCC	0.458	2.302	2.184	2.133	1.862	0.691	0.649	94	91	76	13	10	2.58E-6	> 1.00E-4	> 1.00E-4
EKVX	0.760	2.183	2.050	1.915	1.805	0.767	0.830	91	81	73	.	5	2.09E-6	> 1.00E-4	> 1.00E-4
HOP-62	0.858	2.252	2.115	1.924	2.239	0.895	0.743	90	76	99	3	-13	3.23E-6	1.46E-5	> 1.00E-4
HOP-92	1.121	1.756	1.662	1.628	1.506	0.618	0.580	85	80	61	-45	-48	1.26E-6	3.75E-6	> 1.00E-4
NCI-H226	1.223	2.041	1.925	1.808	1.899	1.154	1.065	86	71	83	-6	-13	2.34E-6	8.63E-6	> 1.00E-4
NCI-H23	0.626	2.117	2.077	2.048	1.888	0.685	0.555	97	95	85	4	-11	2.69E-6	1.81E-5	> 1.00E-4
NCI-H322M	0.737	2.170	2.076	1.968	1.863	0.972	0.998	93	86	79	16	18	2.88E-6	> 1.00E-4	> 1.00E-4
NCI-H460	0.299	2.828	2.925	2.772	2.488	0.172	0.134	104	98	87	-42	-55	1.92E-6	4.69E-6	3.91E-5
NCI-H522	0.971	2.404	2.294	2.258	2.012	0.589	0.706	92	90	73	-39	-27	1.59E-6	4.45E-6	> 1.00E-4
Colon Cancer															
COLO 205	0.587	2.604	2.614	2.520	2.505	0.331	0.305	100	96	95	-44	-48	2.11E-6	4.85E-6	> 1.00E-4
HCC-2998	0.841	2.715	2.643	2.536	2.496	0.255	0.218	96	90	88	-70	-74	1.75E-6	3.62E-6	7.50E-6
HCT-116	0.217	2.159	2.243	1.947	1.045	0.018	0.015	104	89	43	-92	-93	6.94E-7	2.07E-6	4.88E-6
HCT-15	0.353	1.708	1.637	1.522	1.203	0.357	0.316	95	86	63	.	-11	1.60E-6	1.06E-5	> 1.00E-4
HT29	0.309	2.338	2.245	2.130	1.899	0.561	0.530	95	90	78	12	11	2.69E-6	> 1.00E-4	> 1.00E-4
KM12	0.398	2.422	2.370	2.278	1.969	0.645	0.652	97	93	78	12	13	2.64E-6	> 1.00E-4	> 1.00E-4
SW-620	0.295	2.560	2.505	2.412	2.242	0.379	0.323	98	93	86	4	1	2.74E-6	> 1.00E-4	> 1.00E-4
CNS Cancer															
SF-268	1.211	2.839	2.736	2.660	2.531	1.989	1.923	94	89	81	48	44	8.56E-6	> 1.00E-4	> 1.00E-4
SF-539	0.856	2.798	2.774	2.613	2.625	0.539	0.595	99	90	91	-37	-31	2.09E-6	5.14E-6	> 1.00E-4
SNB-19	0.515	2.098	2.019	1.937	1.894	0.692	0.601	95	90	87	11	5	3.08E-6	> 1.00E-4	> 1.00E-4
SNB-75	0.986	1.654	1.483	1.433	1.454	1.100	1.067	74	67	70	17	12	2.39E-6	> 1.00E-4	> 1.00E-4
U251	0.395	2.080	1.963	1.996	1.809	0.387	0.296	93	95	84	-2	-25	2.48E-6	9.44E-6	> 1.00E-4
Melanoma															
LOX IMVI	0.564	3.057	2.975	2.925	2.661	0.169	0.098	97	95	84	-70	-83	1.66E-6	3.51E-6	7.41E-6
MALME-3M	0.780	1.860	1.722	1.709	1.571	0.329	0.392	87	86	73	-58	-50	1.50E-6	3.62E-6	.
M14	0.542	2.302	2.275	2.265	2.006	0.544	0.381	98	98	83	.	-30	2.51E-6	1.01E-5	> 1.00E-4
MDA-MB-435	0.476	2.232	2.173	2.200	1.900	0.563	0.482	97	98	81	5	.	2.56E-6	> 1.00E-4	> 1.00E-4
SK-MEL-2	1.142	2.222	2.152	2.138	1.996	1.036	1.104	94	92	79	-9	-3	2.13E-6	7.85E-6	> 1.00E-4
SK-MEL-28	0.742	2.144	2.153	2.095	2.047	0.621	0.660	101	96	93	-16	-11	2.48E-6	7.09E-6	> 1.00E-4
SK-MEL-5	1.186	3.228	3.212	3.191	3.055	0.903	0.665	99	98	92	-24	-44	2.29E-6	6.21E-6	> 1.00E-4
UACC-257	1.038	2.514	2.415	2.358	2.187	1.052	1.032	93	89	78	1	.	2.30E-6	3.92E-5	> 1.00E-4
UACC-62	0.777	2.908	2.718	2.728	2.342	0.525	0.396	91	92	73	-32	-49	1.66E-6	4.94E-6	> 1.00E-4
Ovarian Cancer															
IGROV1	0.647	2.380	2.357	2.302	2.094	0.496	0.553	99	95	83	-23	-15	2.06E-6	6.05E-6	> 1.00E-4
OVCAR-3	0.467	1.865	1.833	1.795	1.645	0.398	0.370	98	95	84	-15	-21	2.22E-6	7.09E-6	> 1.00E-4
OVCAR-4	0.550	1.351	1.337	1.263	1.143	0.733	0.706	98	89	74	23	19	2.94E-6	> 1.00E-4	> 1.00E-4
OVCAR-5	0.688	1.466	1.369	1.247	1.338	0.443	0.447	87	72	83	-36	-35	1.91E-6	5.02E-6	> 1.00E-4
OVCAR-8	0.486	2.398	2.381	2.283	1.640	0.859	0.869	99	94	60	20	20	1.79E-6	> 1.00E-4	> 1.00E-4
NCI/ADR-RES	0.606	1.990	1.949	1.840	1.615	0.706	0.706	97	89	73	7	7	2.23E-6	> 1.00E-4	> 1.00E-4
SK-OV-3	1.198	2.405	2.364	2.263	2.192	1.890	1.695	97	88	82	57	41	2.83E-5	> 1.00E-4	> 1.00E-4
Renal Cancer															
786-0	0.861	2.665	2.561	2.485	2.569	0.843	0.861	94	90	95	-2	.	2.89E-6	1.00E-4	> 1.00E-4
A498	1.701	2.671	2.477	2.307	2.170	0.122	0.071	80	62	48	-93	-96	7.63E-7	2.20E-6	4.97E-6
ACHN	0.410	1.676	1.595	1.581	1.378	0.210	0.214	94	92	76	-49	-48	1.63E-6	4.08E-6	> 1.00E-4
CAKI-1	0.452	1.462	1.337	1.259	1.057	0.494	0.504	88	80	60	4	5	1.50E-6	> 1.00E-4	> 1.00E-4
RXF 393	1.217	1.995	1.891	1.813	1.692	0.312	0.288	87	77	61	-74	-76	1.21E-6	2.82E-6	6.60E-6
SN12C	0.632	2.551	2.492	2.369	2.091	0.852	0.842	97	91	76	11	11	2.53E-6	> 1.00E-4	> 1.00E-4
TK-10	0.857	1.832	1.739	1.651	1.832	1.218	1.223	90	81	100	37	37	6.22E-6	> 1.00E-4	> 1.00E-4
UO-31	0.517	1.866	1.705	1.638	1.363	0.235	0.298	88	83	63	-55	-42	1.28E-6	3.43E-6	.
Prostate Cancer															
PC-3	0.576	2.176	2.136	2.041	1.675	0.732	0.698	97	92	69	10	8	2.07E-6	> 1.00E-4	> 1.00E-4
DU-145	0.449	2.039	2.019	1.984	1.826	0.340	0.366	99	97	87	-24	-19	2.14E-6	6.03E-6	> 1.00E-4
Breast Cancer															
MCF7	0.554	2.412	2.251	2.264	1.607	0.876	0.901	91	92	57	17	19	1.48E-6	> 1.00E-4	> 1.00E-4
MDA-MB-231/ATCC	0.717	1.741	1.721	1.600	1.600	0.591	0.572	98	86	86	-18	-20	2.23E-6	6.77E-6	> 1.00E-4
HS 578T	1.498	2.633	2.541	2.440	2.328	1.609	1.595	92	83	73	10	9	2.32E-6	> 1.00E-4	> 1.00E-4
BT-549	0.946	2.475	2.334	2.219	2.010	0.235	0.122	91	83	70	-75	-87	1.37E-6	3.02E-6	6.70E-6
MDA-MB-468	1.011	2.074	1.961	1.946	1.777	0.919	0.867	89	88	72	-9	-14	1.87E-6	7.71E-6	> 1.00E-4


National Cancer Institute Developmental Therapeutics Program		NSC : D - 815557/1	Units :Molar	SSPL :0X0S	EXP. ID :1908NS46	
Mean Graphs		Report Date :October 09, 2019		Test Date :August 05, 2019		
Panel/Cell Line	Log ₁₀ GI50	GI50	Log ₁₀ TGI	TGI	Log ₁₀ LC50	LC50
Leukemia						
CCRF-CEM	-5.84		> -4.00		> -4.00	
HL-60(TB)	-5.99		-5.06		> -4.00	
K-562	-5.86		> -4.00		> -4.00	
MOLT-4	-5.91		> -4.00		> -4.00	
RPMI-8226	-5.81		-5.11		> -4.00	
SR	-5.69		> -4.00		> -4.00	
Non-Small Cell Lung Cancer						
A549/ATCC	-5.59		> -4.00		> -4.00	
EKVX	-5.68		> -4.00		> -4.00	
HOP-62	-5.49		-4.84		> -4.00	
HOP-92	-5.90		-5.43		> -4.00	
NCI-H226	-5.63		-5.06		> -4.00	
NCI-H23	-5.57		-4.74		> -4.00	
NCI-H322M	-5.54		> -4.00		> -4.00	
NCI-H460	-5.72		-5.33		-4.41	
NCI-H522	-5.80		-5.35		> -4.00	
Colon Cancer						
COLO 205	-5.67		-5.31		> -4.00	
HCC-2998	-5.76		-5.44		-5.12	
HCT-116	-6.16		-5.68		-5.31	
HCT-15	-5.80		-4.97		> -4.00	
HT29	-5.57		> -4.00		> -4.00	
KM12	-5.58		> -4.00		> -4.00	
SW-620	-5.56		> -4.00		> -4.00	
CNS Cancer						
SF-268	-5.07		> -4.00		> -4.00	
SF-539	-5.68		-5.29		> -4.00	
SNB-19	-5.51		> -4.00		> -4.00	
SNB-75	-5.62		> -4.00		> -4.00	
U251	-5.61		-5.02		> -4.00	
Melanoma						
LOX IMVI	-5.78		-5.45		-5.13	
MALME-3M	-5.82		-5.44			
M14	-5.60		-5.00		> -4.00	
MDA-MB-435	-5.59		> -4.00		> -4.00	
SK-MEL-2	-5.67		-5.11		> -4.00	
SK-MEL-28	-5.61		-5.15		> -4.00	
SK-MEL-5	-5.64		-5.21		> -4.00	
UACC-257	-5.64		-4.41		> -4.00	
UACC-62	-5.78		-5.31		> -4.00	
Ovarian Cancer						
IGROV1	-5.69		-5.22		> -4.00	
OVCAR-3	-5.65		-5.15		> -4.00	
OVCAR-4	-5.53		> -4.00		> -4.00	
OVCAR-5	-5.72		-5.30		> -4.00	
OVCAR-8	-5.75		> -4.00		> -4.00	
NCI/ADR-RES	-5.65		> -4.00		> -4.00	
SK-OV-3	-4.55		> -4.00		> -4.00	
Renal Cancer						
786-0	-5.54		-4.00		> -4.00	
A498	-6.12		-5.66		-5.30	
ACHN	-5.79		-5.39		> -4.00	
CAKI-1	-5.82		> -4.00		> -4.00	
RXF 393	-5.92		-5.55		-5.18	
SN12C	-5.60		> -4.00		> -4.00	
TK-10	-5.21		> -4.00		> -4.00	
UO-31	-5.89		-5.47			
Prostate Cancer						
PC-3	-5.68		> -4.00		> -4.00	
DU-145	-5.67		-5.22		> -4.00	
Breast Cancer						
MCF7	-5.83		> -4.00		> -4.00	
MDA-MB-231/ATCC	-5.65		-5.17		> -4.00	
HS 578T	-5.63		> -4.00		> -4.00	
BT-549	-5.86		-5.52		-5.17	
MDA-MB-468	-5.73		-5.11		> -4.00	

Dose Response Curves


Report Date:October 09, 2019

Test Date:August 05, 2019


All Cell Lines




Leukemia




Non-Small Cell Lung Cancer




Colon Cancer




CNS Cancer




Melanoma




Ovarian Cancer




Renal Cancer



Prostate Cancer



Breast Cancer



National Cancer Institute Developmental Therapeutics Program
In-Vitro Testing Results

NSC : D - 815558 / 1	Experiment ID : 1908NS46	Test Type : 08	Units : Molar
Report Date : October 08, 2019	Test Date : August 05, 2019	QNS :	MC :
COMI : KA2B	Stain Reagent : SRB Dual-Pass Related	SSPL : 0X0S	

Panel/Cell Line	Log10 Concentration												GI50	TGI	LC50
	Time Zero	Ctrl	-8.0	-7.0	-6.0	-5.0	-4.0	-8.0	-7.0	-6.0	-5.0	-4.0			
Leukemia															
CCRF-CEM	0.427	2.539	2.493	2.512	1.146	0.482	0.529	98	99	34	3	5	5.66E-7	> 1.00E-4	> 1.00E-4
HL-60(TB)	0.581	2.265	2.114	2.177	1.340	0.477	0.539	91	95	45	-18	-7	7.95E-7	5.18E-6	> 1.00E-4
K-562	0.163	1.592	1.604	1.552	1.031	0.227	0.275	101	97	61	4	8	1.55E-6	> 1.00E-4	> 1.00E-4
MOLT-4	0.558	2.673	2.592	2.565	1.486	0.565	0.636	96	95	44	.	4	7.59E-7	> 1.00E-4	> 1.00E-4
RPMI-8226	0.652	2.499	2.505	2.570	1.676	0.475	0.526	100	104	55	-27	-19	1.16E-6	4.68E-6	> 1.00E-4
SR	0.160	0.546	0.490	0.495	0.358	0.192	0.210	85	87	51	8	13	1.07E-6	> 1.00E-4	> 1.00E-4
Non-Small Cell Lung Cancer															
A549/ATCC	0.458	2.327	2.253	2.321	1.912	0.524	0.518	96	100	78	4	3	2.37E-6	> 1.00E-4	> 1.00E-4
EKVX	0.760	2.319	2.059	1.931	1.827	0.758	0.672	83	75	68	.	-12	1.85E-6	9.89E-6	> 1.00E-4
HOP-62	0.858	2.288	2.192	2.191	2.193	0.702	0.513	93	93	93	-18	-40	2.45E-6	6.86E-6	> 1.00E-4
HOP-92	1.121	1.816	1.720	1.710	1.578	0.422	0.345	86	85	66	-62	-69	1.33E-6	3.26E-6	8.00E-6
NCI-H226	1.223	2.053	1.907	1.878	1.920	0.907	0.776	82	79	84	-26	-37	2.04E-6	5.82E-6	> 1.00E-4
NCI-H23	0.626	2.089	1.968	2.023	1.835	0.688	0.430	92	96	83	4	-31	2.61E-6	1.32E-5	> 1.00E-4
NCI-H322M	0.737	2.193	2.027	1.966	1.853	0.932	0.848	89	84	77	13	8	2.64E-6	> 1.00E-4	> 1.00E-4
NCI-H460	0.299	2.818	2.750	2.874	2.330	0.116	0.122	97	102	81	-61	-59	1.64E-6	3.70E-6	8.34E-6
NCI-H522	0.971	2.321	2.321	2.262	2.164	0.281	0.260	100	96	88	-71	-73	1.74E-6	3.58E-6	7.38E-6
Colon Cancer															
COLO 205	0.587	2.560	2.490	2.581	2.403	0.152	0.118	96	101	92	-74	-80	1.79E-6	3.58E-6	7.16E-6
HCC-2998	0.841	2.666	2.527	2.614	2.387	0.290	0.162	92	97	85	-66	-81	1.70E-6	3.66E-6	7.88E-6
HCT-116	0.217	2.227	2.175	2.026	0.925	0.066	0.061	97	90	35	-70	-72	5.37E-7	2.16E-6	6.48E-6
HCT-15	0.353	1.733	1.572	1.564	1.114	0.308	0.293	88	88	55	-13	-17	1.19E-6	6.46E-6	> 1.00E-4
HT29	0.309	2.268	2.206	2.178	1.709	0.284	0.262	97	95	71	-8	-15	1.86E-6	7.88E-6	> 1.00E-4
KM12	0.398	2.437	2.306	2.430	1.910	0.458	0.467	94	100	74	3	3	2.18E-6	> 1.00E-4	> 1.00E-4
SW-620	0.295	2.474	2.378	2.431	1.967	0.334	0.424	96	98	77	2	6	2.27E-6	> 1.00E-4	> 1.00E-4
CNS Cancer															
SF-268	1.211	2.742	2.590	2.536	2.344	1.787	1.771	90	87	74	38	37	4.56E-6	> 1.00E-4	> 1.00E-4
SF-539	0.856	2.874	2.708	2.662	2.517	0.343	0.246	92	90	82	-60	-71	1.69E-6	3.79E-6	8.52E-6
SNB-19	0.515	2.133	2.072	2.060	1.808	0.679	0.564	96	96	80	10	3	2.68E-6	> 1.00E-4	> 1.00E-4
SNB-75	0.986	1.639	1.486	1.490	1.377	0.866	0.912	76	77	60	-12	-8	1.37E-6	6.77E-6	> 1.00E-4
U251	0.395	2.169	1.895	1.998	1.841	0.246	0.142	85	90	82	-38	-64	1.84E-6	4.82E-6	2.89E-5
Melanoma															
LOX IMVI	0.564	3.014	2.928	2.856	2.696	0.096	0.056	97	94	87	-83	-90	1.65E-6	3.25E-6	6.40E-6
MALME-3M	0.780	1.908	1.793	1.785	1.702	0.209	0.183	90	89	82	-73	-77	1.60E-6	3.37E-6	7.08E-6
M14	0.542	2.404	2.334	2.361	2.088	0.451	0.401	96	98	83	-17	-26	2.14E-6	6.78E-6	> 1.00E-4
MDA-MB-435	0.476	2.172	2.160	2.225	1.864	0.333	0.310	99	103	82	-30	-35	1.93E-6	5.39E-6	> 1.00E-4
SK-MEL-2	1.142	2.195	2.223	2.199	2.226	0.787	0.763	103	100	103	-31	-33	2.48E-6	5.86E-6	> 1.00E-4
SK-MEL-28	0.742	2.159	2.214	2.262	1.965	0.478	0.408	104	107	86	-36	-45	1.98E-6	5.10E-6	> 1.00E-4
SK-MEL-5	1.186	3.236	3.216	3.215	3.140	0.463	0.180	99	99	95	-61	-85	1.95E-6	4.07E-6	8.50E-6
UACC-257	1.038	2.518	2.483	2.543	2.369	0.711	0.665	98	102	90	-32	-36	2.13E-6	5.50E-6	> 1.00E-4
UACC-62	0.777	2.937	2.815	2.861	2.398	0.478	0.339	94	97	75	-39	-56	1.66E-6	4.58E-6	4.39E-5
Ovarian Cancer															
IGROV1	0.647	2.377	2.377	2.405	2.116	0.496	0.420	100	102	85	-23	-35	2.10E-6	6.09E-6	> 1.00E-4
OVCAR-3	0.467	1.769	1.701	1.659	1.409	0.150	0.266	95	91	72	-68	-43	1.44E-6	3.28E-6	.
OVCAR-4	0.550	1.330	1.263	1.266	1.103	0.547	0.613	91	92	71	.	8	1.96E-6	.	> 1.00E-4
OVCAR-5	0.688	1.496	1.269	1.297	1.269	0.443	0.345	72	75	72	-36	-50	1.60E-6	4.66E-6	> 1.00E-4
OVCAR-8	0.486	2.442	2.367	2.392	1.614	0.657	0.720	96	97	58	9	12	1.43E-6	> 1.00E-4	> 1.00E-4
NCI/ADR-RES	0.606	1.926	1.818	1.896	1.640	0.569	0.558	92	98	78	-6	-8	2.16E-6	8.47E-6	> 1.00E-4
SK-OV-3	1.198	2.394	2.353	2.398	2.317	1.596	1.429	97	100	94	33	19	5.28E-6	> 1.00E-4	> 1.00E-4
Renal Cancer															
786-0	0.861	2.711	2.597	2.588	2.570	0.714	0.618	94	93	92	-17	-28	2.44E-6	6.98E-6	> 1.00E-4
A498	1.701	2.631	2.434	2.385	2.257	0.093	0.150	79	74	60	-95	-91	1.16E-6	2.44E-6	5.14E-6
ACHN	0.410	1.694	1.647	1.675	1.352	0.040	0.040	96	99	73	-90	-90	1.39E-6	2.81E-6	5.67E-6
CAKI-1	0.452	1.400	1.315	1.184	0.932	0.262	0.288	91	77	51	-42	-36	1.02E-6	3.52E-6	> 1.00E-4
RXF 393	1.217	1.963	1.917	1.862	1.699	0.284	0.241	94	86	65	-77	-80	1.27E-6	2.87E-6	6.48E-6
SN12C	0.632	2.638	2.542	2.579	2.144	0.767	0.791	95	97	75	7	8	2.34E-6	> 1.00E-4	> 1.00E-4
TK-10	0.857	1.743	1.633	1.481	1.712	0.892	0.807	88	70	96	4	-6	3.18E-6	2.51E-5	> 1.00E-4
UO-31	0.517	1.884	1.660	1.614	1.296	0.063	0.065	84	80	57	-88	-88	1.12E-6	2.47E-6	5.48E-6
Prostate Cancer															
PC-3	0.576	2.127	2.065	2.101	1.506	0.545	0.532	96	98	60	-5	-8	1.42E-6	8.27E-6	> 1.00E-4
DU-145	0.449	1.934	1.969	1.913	1.707	0.201	0.167	102	99	85	-55	-63	1.77E-6	4.03E-6	9.16E-6
Breast Cancer															
MCF7	0.554	2.403	2.234	2.249	1.435	0.702	0.719	91	92	48	8	9	8.85E-7	> 1.00E-4	> 1.00E-4
MDA-MB-231/ATCC	0.717	1.822	1.769	1.703	1.587	0.328	0.306	95	89	79	-54	-57	1.64E-6	3.91E-6	9.28E-6
HS 578T	1.498	2.713	2.600	2.606	2.415	1.165	1.275	91	91	75	-22	-15	1.82E-6	5.92E-6	> 1.00E-4
BT-549	0.946	2.594	2.405	2.469	2.120	0.154	0.100	89	92	71	-84	-89	1.37E-6	2.88E-6	6.05E-6
MDA-MB-468	1.011	2.075	1.960	2.009	1.838	0.775	0.623	89	94	78	-23	-38	1.88E-6	5.87E-6	> 1.00E-4


National Cancer Institute Developmental Therapeutics Program		NSC : D - 815558/1	Units :Molar	SSPL :0X0S	EXP. ID :1908NS46	
Mean Graphs		Report Date :October 08, 2019		Test Date :August 05, 2019		
Panel/Cell Line	Log ₁₀ GI50	GI50	Log ₁₀ TGI	TGI	Log ₁₀ LC50	LC50
Leukemia						
CCRF-CEM	-6.25		> -4.00		> -4.00	
HL-60(TB)	-6.10		-5.29		> -4.00	
K-562	-5.81		> -4.00		> -4.00	
MOLT-4	-6.12		> -4.00		> -4.00	
RPMI-8226	-5.93		-5.33		> -4.00	
SR	-5.97		> -4.00		> -4.00	
Non-Small Cell Lung Cancer						
A549/ATCC	-5.63		> -4.00		> -4.00	
EKVX	-5.73		-5.00		> -4.00	
HOP-62	-5.61		-5.16		> -4.00	
HOP-92	-5.88		-5.49		-5.10	
NCI-H226	-5.69		-5.24		> -4.00	
NCI-H23	-5.58		-4.88		> -4.00	
NCI-H322M	-5.58		> -4.00		> -4.00	
NCI-H460	-5.78		-5.43		-5.08	
NCI-H522	-5.76		-5.45		-5.13	
Colon Cancer						
COLO 205	-5.75		-5.45		-5.15	
HCC-2998	-5.77		-5.44		-5.10	
HCT-116	-6.27		-5.66		-5.19	
HCT-15	-5.93		-5.19		> -4.00	
HT29	-5.73		-5.10		> -4.00	
KM12	-5.66		> -4.00		> -4.00	
SW-620	-5.64		> -4.00		> -4.00	
CNS Cancer						
SF-268	-5.34		> -4.00		> -4.00	
SF-539	-5.77		-5.42		-5.07	
SNB-19	-5.57		> -4.00		> -4.00	
SNB-75	-5.86		-5.17		> -4.00	
U251	-5.74		-5.32		-4.54	
Melanoma						
LOX IMVI	-5.78		-5.49		-5.19	
MALME-3M	-5.80		-5.47		-5.15	
M14	-5.67		-5.17		> -4.00	
MDA-MB-435	-5.72		-5.27		> -4.00	
SK-MEL-2	-5.61		-5.23		> -4.00	
SK-MEL-28	-5.70		-5.29		> -4.00	
SK-MEL-5	-5.71		-5.39		-5.07	
UACC-257	-5.67		-5.26		> -4.00	
UACC-62	-5.78		-5.34		-4.36	
Ovarian Cancer						
IGROV1	-5.68		-5.22		> -4.00	
OVCAR-3	-5.84		-5.48		> -4.00	
OVCAR-4	-5.71				> -4.00	
OVCAR-5	-5.80		-5.33		> -4.00	
OVCAR-8	-5.84		> -4.00		> -4.00	
NCI/ADR-RES	-5.66		-5.07		> -4.00	
SK-OV-3	-5.28		> -4.00		> -4.00	
Renal Cancer						
786-0	-5.61		-5.16		> -4.00	
A498	-5.94		-5.61		-5.29	
ACHN	-5.86		-5.55		-5.25	
CAKI-1	-5.99		-5.45		> -4.00	
RXF 393	-5.90		-5.54		-5.19	
SN12C	-5.63		> -4.00		> -4.00	
TK-10	-5.50		-4.60		> -4.00	
UO-31	-5.95		-5.61		-5.26	
Prostate Cancer						
PC-3	-5.85		-5.08		> -4.00	
DU-145	-5.75		-5.40		-5.04	
Breast Cancer</						

Dose Response Curves


Report Date:October 08, 2019

Test Date:August 05, 2019


All Cell Lines




Leukemia




Non-Small Cell Lung Cancer




Colon Cancer




CNS Cancer




Melanoma




Ovarian Cancer




Renal Cancer



Prostate Cancer



Breast Cancer




National Cancer Institute Developmental Therapeutics Program
In-Vitro Testing Results


NSC : D - 815561 / 1			Experiment ID : 1908NS46					Test Type : 08			Units : Molar				
Report Date : October 09, 2019			Test Date : August 05, 2019					QNS :			MC :				
COMI : CC 133			Stain Reagent : SRB Dual-Pass Related					SSPL : 0X0S							
Log10 Concentration															
Panel/Cell Line	Time Zero	Ctrl	-8.0	-7.0	-6.0	-5.0	-4.0	-8.0	-7.0	-6.0	-5.0	-4.0	GI50	TGI	LC50
Leukemia															
CCRF-CEM	0.427	2.707	2.567	2.282	0.570	0.519	0.494	94	81	6	4	3	2.62E-7	> 1.00E-4	> 1.00E-4
HL-60(TB)	0.581	2.451	2.335	1.955	0.545	0.503	0.505	94	73	-6	-13	-13	1.97E-7	8.34E-7	> 1.00E-4
K-562	0.163	1.784	1.746	1.468	0.191	0.177	0.189	98	81	2	1	2	2.44E-7	> 1.00E-4	> 1.00E-4
MOLT-4	0.558	2.621	2.705	2.329	0.692	0.668	0.631	104	86	6	5	4	2.83E-7	> 1.00E-4	> 1.00E-4
SRPMI-8226	0.652	2.611	2.531	2.394	0.475	0.460	0.463	96	89	-27	-29	-29	2.16E-7	5.83E-7	> 1.00E-4
SP	0.160	0.519	0.478	0.413	0.178	0.175	0.173	88	70	5	4	4	2.05E-7	> 1.00E-4	> 1.00E-4
Non-Small Cell Lung Cancer															
A549/ATCC	0.458	2.437	2.350	2.295	0.456	0.439	0.446	96	93	.	-4	-3	2.88E-7	9.89E-7	> 1.00E-4
EKVX	0.760	2.306	2.139	2.108	0.887	0.565	0.686	89	87	8	-26	-10	2.96E-7	1.75E-6	> 1.00E-4
HOP-62	0.858	2.390	2.327	2.321	0.802	0.764	0.800	96	96	-7	-11	-7	2.79E-7	8.62E-7	> 1.00E-4
HOP-92	1.121	1.826	1.703	1.708	0.472	0.392	0.440	83	83	-58	-65	-61	1.72E-7	3.89E-7	8.79E-7
NCI-H226	1.223	2.051	1.950	1.901	1.138	0.850	0.943	88	82	-7	-30	-23	2.28E-7	8.34E-7	> 1.00E-4
NCI-H23	0.626	2.082	2.096	2.073	0.509	0.419	0.503	101	99	-19	-33	-20	2.62E-7	6.94E-7	> 1.00E-4
NCI-H322M	0.737	2.209	2.136	2.120	0.838	0.768	0.773	95	94	7	2	2	3.19E-7	> 1.00E-4	> 1.00E-4
NCI-H460	0.299	2.885	2.869	2.844	0.177	0.178	0.206	99	98	-41	-40	-31	2.23E-7	5.09E-7	> 1.00E-4
NCI-H522	0.971	2.550	2.420	2.460	0.505	0.388	0.451	92	94	-48	-60	-54	2.05E-7	4.60E-7	1.47E-6
Colon Cancer															
COLO 205	0.587	2.667	2.590	2.717	0.215	0.184	0.200	96	102	-63	-69	-66	2.07E-7	4.14E-7	8.30E-7
HCC-2998	0.841	2.713	2.600	2.573	0.194	0.140	0.158	94	93	-77	-83	-81	1.78E-7	3.52E-7	6.94E-7
HCT-116	0.217	2.216	2.057	1.820	0.060	0.038	0.057	92	80	-72	-83	-74	1.58E-7	3.35E-7	7.14E-7
HCT-15	0.353	1.773	1.649	1.433	0.317	0.244	0.298	91	76	-10	-31	-16	2.00E-7	7.59E-7	> 1.00E-4
HT29	0.309	2.331	2.472	2.365	0.370	0.328	0.300	107	102	3	1	-3	3.34E-7	1.75E-5	> 1.00E-4
KM12	0.398	2.548	2.450	2.518	0.581	0.500	0.454	95	99	8	5	3	3.46E-7	> 1.00E-4	> 1.00E-4
SW-620	0.295	2.524	2.450	2.435	0.333	0.286	0.387	97	96	2	-3	4	3.08E-7	.	> 1.00E-4
CNS Cancer															
SF-268	1.211	2.862	2.769	2.754	1.869	1.485	1.632	94	93	40	17	26	6.47E-7	> 1.00E-4	> 1.00E-4
SF-539	0.856	2.894	2.742	2.850	0.422	0.214	0.212	93	98	-51	-75	-75	2.10E-7	4.56E-7	9.89E-7
SNB-19	0.515	2.125	2.058	2.034	0.456	0.204	0.273	96	94	-12	-60	-47	2.62E-7	7.78E-7	.
SNB-75	0.986	1.688	1.506	1.575	0.993	0.522	0.735	74	84	1	-47	-26	2.56E-7	1.05E-6	> 1.00E-4
U251	0.395	2.290	2.081	2.056	0.178	0.145	0.156	89	88	-55	-63	-61	1.84E-7	4.11E-7	9.22E-7
Melanoma															
LOX IMVI	0.564	3.090	3.015	2.855	0.153	0.112	0.120	97	91	-73	-80	-79	1.77E-7	3.58E-7	7.24E-7
MALME-3M	0.780	1.892	1.759	1.767	0.340	0.252	0.289	88	89	-56	-68	-63	1.85E-7	4.09E-7	9.02E-7
M14	0.542	2.279	2.227	2.163	0.585	0.378	0.436	97	93	2	-30	-20	3.00E-7	1.19E-6	> 1.00E-4
MDA-MB-435	0.476	2.343	2.241	2.316	0.467	0.418	0.413	95	99	-2	-12	-13	3.04E-7	9.55E-7	> 1.00E-4
SK-MEL-2	1.142	2.183	2.267	2.298	1.276	0.910	0.985	108	111	13	-20	-14	4.18E-7	2.44E-6	> 1.00E-4
SK-MEL-28	0.742	2.232	2.298	2.271	0.552	0.523	0.545	104	103	-26	-30	-27	2.57E-7	6.31E-7	> 1.00E-4
SK-MEL-5	1.186	3.215	3.196	3.173	0.886	0.119	0.169	99	98	-25	-90	-86	2.45E-7	6.23E-7	2.41E-6
UACC-257	1.038	2.639	2.518	2.573	1.064	0.678	0.788	92	96	2	-35	-24	3.06E-7	1.11E-6	> 1.00E-4
UACC-62	0.777	2.919	2.818	2.714	0.395	0.269	0.275	95	90	-49	-65	-65	1.95E-7	4.44E-7	1.13E-6
Ovarian Cancer															
IGROV1	0.647	2.392	2.374	2.368	0.529	0.402	0.497	99	99	-18	-38	-23	2.60E-7	6.97E-7	> 1.00E-4
OVCAR-3	0.467	1.906	1.901	1.863	0.299	0.195	0.219	100	97	-36	-58	-53	2.25E-7	5.36E-7	4.22E-6
OVCAR-4	0.550	1.359	1.317	1.246	0.634	0.580	0.611	95	86	10	4	7	2.99E-7	> 1.00E-4	> 1.00E-4
OVCAR-5	0.688	1.509	1.355	1.364	0.272	0.226	0.234	81	82	-60	-67	-66	1.68E-7	3.77E-7	8.45E-7
OVCAR-8	0.486	2.523	2.366	2.030	0.777	0.680	0.824	92	76	14	10	17	2.62E-7	> 1.00E-4	> 1.00E-4
NCI/ADR-RES	0.606	2.014	1.910	1.857	0.744	0.646	0.718	93	89	10	3	8	3.10E-7	> 1.00E-4	> 1.00E-4
SK-OV-3	1.198	2.451	2.459	2.425	1.855	1.441	1.509	101	98	52	19	25	1.19E-6	> 1.00E-4	> 1.00E-4
Renal Cancer															
786-0	0.861	2.612	2.557	2.473	0.146	0.053	0.086	97	92	-83	-94	-90	1.74E-7	3.35E-7	6.48E-7
A498	1.701	2.616	2.552	2.368	0.422	0.098	0.112	93	73	-75	-94	-93	1.43E-7	3.10E-7	6.76E-7
ACHN	0.410	1.722	1.682	1.661	0.088	0.043	0.074	97	95	-79	-90	-82	1.82E-7	3.53E-7	6.84E-7
CAKI-1	0.452	1.459	1.314	1.200	0.265	0.209	0.231	86	74	-41	-54	-49	1.62E-7	4.39E-7	.
RXF 393	1.217	1.945	1.886	1.816	0.247	0.159	0.156	92	82	-80	-87	-87	1.58E-7	3.22E-7	6.56E-7
SN12C	0.632	2.685	2.558	2.433	0.579	0.509	0.572	94	88	-8	-20	-9	2.47E-7	8.17E-7	> 1.00E-4
TK-10	0.857	1.826	1.792	1.776	1.099	0.802	1.045	96	95	25	-6	19	4.39E-7	.	> 1.00E-4
UO-31	0.517	1.865	1.709	1.622	0.040	0.029	0.030	88	82	-92	-94	-94	1.53E-7	2.95E-7	5.72E-7
Prostate Cancer															
PC-3	0.576	2.224	2.160	2.080	0.507	0.365	0.431	96	91	-12	-37	-25	2.51E-7	7.65E-7	> 1.00E-4
DU-145	0.449	2.063	2.008	1.991	0.173	0.134	0.136	97	96	-61	-70	-70	1.95E-7	4.06E-7	8.45E-7
Breast Cancer															
MCF7	0.554	2.472	2.299	2.134	0.832	0.616	0.643	91	82	14	3	5	3.00E-7	> 1.00E-4	> 1.00E-4
MDA-MB-231/ATCC	0.717	1.712	1.671	1.620	0.504	0.554	0.556	96	91	-30	-23	-23	2.18E-7	5.66E-7	> 1.00E-4
HS 578T	1.498	2.729	2.636	2.606	1.729	1.442	1.667	92	90	19	-4	14	3.64E-7	.	> 1.00E-4
BT-549	0.946	2.492	2.413	2.266	0.316	0.182	0.331	95	85	-67	-81	-65	1.71E-7	3.65E-7	7.78E-7
MDA-MB-468	1.011	2.062	1.944	2.064	0.767	0.694	0.694	89	100	-24	-31	-31	2.53E-7	6.39E-7	> 1.00E-4

National Cancer Institute Developmental Therapeutics Program		NSC : D - 815561/1		Units :Molar		SSPL :0X0S		EXP. ID :1908NS46	
Mean Graphs		Report Date :October 09, 2019				Test Date :August 05, 2019			
Panel/Cell Line	Log ₁₀ GI50	GI50	Log ₁₀ TGI	TGI	Log ₁₀ LC50	LC50			
Leukemia									
CCRF-CEM	-6.58		> -4.00		> -4.00				
HL-60(TB)	-6.71		-6.08		> -4.00				
K-562	-6.61		> -4.00		> -4.00				
MOLT-4	-6.55		> -4.00		> -4.00				
RPMI-8226	-6.66		-6.23		> -4.00				
SR	-6.69		> -4.00		> -4.00				
Non-Small Cell Lung Cancer									
A549/ATCC	-6.54		-6.00		> -4.00				
EKVX	-6.53		-5.76		> -4.00				
HOP-62	-6.55		-6.06		> -4.00				
HOP-92	-6.76		-6.41		-6.06				
NCI-H226	-6.64		-6.08		> -4.00				
NCI-H23	-6.58		-6.16		> -4.00				
NCI-H322M	-6.50		> -4.00		> -4.00				
NCI-H460	-6.65		-6.29		> -4.00				
NCI-H522	-6.69		-6.34		-5.83				
Colon Cancer									
COLO 205	-6.68		-6.38		-6.08				
HCC-2998	-6.75		-6.45		-6.16				
HCT-116	-6.80		-6.47		-6.15				
HCT-15	-6.70		-6.12		> -4.00				
HT29	-6.48		-4.76		> -4.00				
KM12	-6.46		> -4.00		> -4.00				
SW-620	-6.51				> -4.00				
CNS Cancer									
SF-268	-6.19		> -4.00		> -4.00				
SF-539	-6.68		-6.34		-6.00				
SNB-19	-6.58		-6.11						
SNB-75	-6.59		-5.98		> -4.00				
U251	-6.74		-6.39		-6.04				
Melanoma									
LOX IMVI	-6.75		-6.45		-6.14				
MALME-3M	-6.73		-6.39		-6.04				
M14	-6.52		-5.93		> -4.00				
MDA-MB-435	-6.52		-6.02		> -4.00				
SK-MEL-2	-6.38		-5.61		> -4.00				
SK-MEL-28	-6.59		-6.20		> -4.00				
SK-MEL-5	-6.61		-6.21		-5.62				
UACC-257	-6.51		-5.96		> -4.00				
UACC-62	-6.71		-6.35		-5.95				
Ovarian Cancer									
IGROV1	-6.58		-6.16		> -4.00				
OVCAR-3	-6.65		-6.27		-5.38				
OVCAR-4	-6.52		> -4.00		> -4.00				
OVCAR-5	-6.77		-6.42		-6.07				
OVCAR-8	-6.58		> -4.00		> -4.00				
NCI/ADR-RES	-6.51		> -4.00		> -4.00				
SK-OV-3	-5.93		> -4.00		>				


All Cell Lines




Leukemia




Non-Small Cell Lung Cancer




Colon Cancer




CNS Cancer




Melanoma




Ovarian Cancer




Renal Cancer



Prostate Cancer



Breast Cancer



National Cancer Institute Developmental Therapeutics Program
In-Vitro Testing Results


NSC : D - 815562 / 1				Experiment ID : 1908NS46				Test Type : 08				Units : Molar			
Report Date : October 09, 2019				Test Date : August 05, 2019				QNS :				MC :			
COMI : CC 163				Stain Reagent : SRB Dual-Pass Related				SSPL : 0X0S							
Log10 Concentration															
Panel/Cell Line	Time Zero	Ctrl	-8.0	-7.0	-6.0	-5.0	-4.0	-8.0	-7.0	-6.0	-5.0	-4.0	GI50	TGI	LC50
Leukemia															
CCRF-CEM	0.427	2.707	2.756	2.712	0.685	0.607	1.295	102	100	11	8	38	3.67E-7	> 1.00E-4	> 1.00E-4
HL-60(TB)	0.581	2.451	2.416	2.225	1.134	0.802	1.895	98	88	30	12	70	.	> 1.00E-4	> 1.00E-4
K-562	0.163	1.784	1.746	1.644	0.347	0.250	1.306	98	91	11	5	70	.	> 1.00E-4	> 1.00E-4
MOLT-4	0.558	2.621	2.653	2.665	0.741	0.685	1.797	102	102	9	6	60	.	> 1.00E-4	> 1.00E-4
RPMI-8226	0.652	2.611	2.688	2.734	0.799	0.638	2.074	104	106	7	-2	73	.	.	> 1.00E-4
SR	0.160	0.519	0.470	0.483	0.215	0.211	0.420	86	90	15	14	72	.	> 1.00E-4	> 1.00E-4
Non-Small Cell Lung Cancer															
A549/ATCC	0.458	2.437	2.306	2.206	1.402	0.725	2.089	93	88	48	13	82	.	> 1.00E-4	> 1.00E-4
EKVX	0.760	2.306	2.157	2.122	1.563	0.878	1.904	90	88	52	8	74	.	> 1.00E-4	> 1.00E-4
HOP-62	0.858	2.390	2.361	2.181	1.953	1.186	2.041	98	86	71	21	77	.	> 1.00E-4	> 1.00E-4
HOP-92	1.121	1.826	1.762	1.710	1.325	0.492	1.480	91	84	29	-56	51	.	.	.
NCI-H226	1.223	2.051	1.971	1.898	1.887	1.332	1.801	90	81	80	13	70	.	> 1.00E-4	> 1.00E-4
NCI-H23	0.626	2.082	2.110	2.073	1.231	0.628	1.841	102	99	42	.	83	.	> 1.00E-4	> 1.00E-4
NCI-H322M	0.737	2.209	2.103	1.996	1.725	1.289	1.920	93	86	67	37	80	.	> 1.00E-4	> 1.00E-4
NCI-H460	0.299	2.885	2.959	2.894	1.187	0.358	2.568	103	100	34	2	88	.	> 1.00E-4	> 1.00E-4
NCI-H522	0.971	2.550	2.347	2.374	1.070	0.443	2.108	87	89	6	-54	72	.	.	.
Colon Cancer															
COLO 205	0.587	2.667	2.675	2.707	1.707	0.409	2.437	100	102	54	-30	89	.	.	> 1.00E-4
HCC-2998	0.841	2.713	2.656	2.565	1.608	0.218	2.508	97	92	41	-74	89	.	.	.
HCT-116	0.217	2.216	2.230	2.062	0.117	0.057	1.247	101	92	-46	-74	52	.	.	.
HCT-15	0.353	1.773	1.660	1.616	0.515	0.385	1.245	92	89	11	2	63	.	> 1.00E-4	> 1.00E-4
HT29	0.309	2.331	2.360	2.266	0.458	0.443	1.880	101	97	7	7	78	.	> 1.00E-4	> 1.00E-4
KM12	0.398	2.548	2.500	2.471	1.155	0.671	1.930	98	96	35	13	71	.	> 1.00E-4	> 1.00E-4
SW-620	0.295	2.524	2.546	2.346	0.623	0.441	2.242	101	92	15	7	87	.	> 1.00E-4	> 1.00E-4
CNS Cancer															
SF-268	1.211	2.862	2.723	2.702	2.478	2.162	2.549	92	90	77	58	81	> 1.00E-4	> 1.00E-4	> 1.00E-4
SF-539	0.856	2.894	2.800	2.730	0.760	0.284	2.561	95	92	-11	-67	84	.	.	.
SNB-19	0.515	2.125	2.041	1.991	1.022	0.749	1.559	95	92	31	15	65	.	> 1.00E-4	> 1.00E-4
SNB-75	0.986	1.688	1.522	1.446	1.334	1.045	1.215	76	65	50	8	33	9.40E-7	> 1.00E-4	> 1.00E-4
U251	0.395	2.290	2.173	2.112	0.625	0.329	1.566	94	91	12	-17	62	.	.	> 1.00E-4
Melanoma															
LOX IMVI	0.564	3.090	2.988	2.930	0.379	0.067	2.678	96	94	-33	-88	84	.	.	.
MALME-3M	0.780	1.892	1.759	1.730	0.626	0.375	1.572	88	85	-20	-52	71	.	.	.
M14	0.542	2.279	2.221	2.195	0.887	0.681	1.918	97	95	20	8	79	.	> 1.00E-4	> 1.00E-4
MDA-MB-435	0.476	2.343	2.309	2.199	0.663	0.501	2.071	98	92	10	1	85	.	> 1.00E-4	> 1.00E-4
SK-MEL-2	1.142	2.183	2.201	2.153	1.933	1.290	2.006	102	97	76	14	83	.	> 1.00E-4	> 1.00E-4
SK-MEL-28	0.742	2.232	2.228	2.171	0.975	0.598	2.034	100	96	16	-19	87	.	.	> 1.00E-4
SK-MEL-5	1.186	3.215	3.182	3.198	2.734	1.134	3.069	98	99	76	-4	93	.	.	> 1.00E-4
UACC-257	1.038	2.639	2.498	2.435	1.894	1.180	2.370	91	87	53	9	83	.	> 1.00E-4	> 1.00E-4
UACC-62	0.777	2.919	2.752	2.655	1.274	0.489	2.348	92	88	23	-37	73	.	.	> 1.00E-4
Ovarian Cancer															
IGROV1	0.647	2.392	2.401	2.281	0.856	0.504	1.915	101	94	12	-22	73	.	.	> 1.00E-4
OVCAR-3	0.467	1.906	1.919	1.876	0.632	0.445	1.552	101	98	11	-5	75	.	.	> 1.00E-4
OVCAR-4	0.550	1.359	1.331	1.279	0.816	0.734	1.064	97	90	33	23	63	.	> 1.00E-4	> 1.00E-4
OVCAR-5	0.688	1.509	1.409	1.376	1.093	0.387	1.348	88	84	49	-44	80	.	.	> 1.00E-4
OVCAR-8	0.486	2.523	2.396	2.380	1.194	0.950	1.620	94	93	35	23	56	.	> 1.00E-4	> 1.00E-4
NCI/ADR-RES	0.606	2.014	1.991	1.886	1.112	0.786	1.664	98	91	36	13	75	.	> 1.00E-4	> 1.00E-4
SK-OV-3	1.198	2.451	2.341	2.312	2.154	1.989	2.174	91	89	76	63	78	> 1.00E-4	> 1.00E-4	> 1.00E-4
Renal Cancer															
786-0	0.861	2.612	2.567	2.554	1.537	0.784	2.218	97	97	39	-9	77	.	.	> 1.00E-4
A498	1.701	2.616	2.501	2.470	2.029	0.277	2.406	87	84	36	-84	77	.	.	.
ACHN	0.410	1.722	1.649	1.689	0.154	0.146	1.332	94	97	-63	-64	70	.	.	.
CAKI-1	0.452	1.459	1.338	1.311	0.780	0.576	1.038	88	85	33	12	58	.	> 1.00E-4	> 1.00E-4
RXF 393	1.217	1.945	1.880	1.827	1.066	0.127	1.598	91	84	-12	-90	52	.	.	.
SN12C	0.632	2.685	2.567	2.382	1.103	0.793	2.056	94	85	23	8	69	.	> 1.00E-4	> 1.00E-4
TK-10	0.857	1.826	1.776	1.750	1.413	1.265	1.946	95	92	57	42	112	.	> 1.00E-4	> 1.00E-4
UO-31	0.517	1.865	1.688	1.655	0.420	0.036	1.260	87	84	-19	-93	55	.	.	.
Prostate Cancer															
PC-3	0.576	2.224	2.138	2.079	1.095	0.753	1.534	95	91	31	11	58	.	> 1.00E-4	> 1.00E-4
DU-145	0.449	2.063	2.101	1.996	1.087	0.453	1.800	102	96	39	.	84	.	> 1.00E-4	> 1.00E-4
Breast Cancer															
MCF7	0.554	2.472	2.300	2.261	1.147	1.101	1.892	91	89	31	29	70	.	> 1.00E-4	> 1.00E-4
MDA-MB-231/ATCC	0.717	1.712	1.711	1.600	1.095	0.356	1.344	100	89	38	-50	63	.	.	.
HS 578T	1.498	2.729	2.627	2.581	2.108	1.660	2.191	92	88	50	13	56	.	> 1.00E-4	> 1.00E-4
BT-549	0.946	2.492	2.412	2.317	1.290	0.471	2.030	95	89	22	-50	70	.	.	.
MDA-MB-468	1.011	2.062	1.976	1.974	1.561	0.978	1.898	92	92	52	-3	84	.	.	> 1.00E-4

Dose Response Curves


Report Date:October 09, 2019

Test Date:August 05, 2019


All Cell Lines




Leukemia




Non-Small Cell Lung Cancer




Colon Cancer




CNS Cancer




Melanoma




Ovarian Cancer




Renal Cancer



Prostate Cancer



Breast Cancer



National Cancer Institute Developmental Therapeutics Program
In-Vitro Testing Results


NSC : D - 803357 / 1	Experiment ID : 1802NS38	Test Type : 08	Units : Molar
Report Date : March 08, 2018	Test Date : February 12, 2018	QNS :	MC :
COMI : CC-39	Stain Reagent : SRB Dual-Pass Related	SSPL : 0X0S	

Panel/Cell Line	Log10 Concentration														
	Time Zero	Ctrl	-8.0	-7.0	-6.0	-5.0	-4.0	-8.0	-7.0	-6.0	-5.0	-4.0	GI50	TGI	LC50
Leukemia															
CCRF-CEM	0.459	2.762	2.726	2.731	2.448	0.479	0.371	98	99	86	1	-19	2.66E-6	1.10E-5	> 1.00E-4
HL-60(TB)	0.772	2.455	2.292	1.487	1.003	0.507	0.455	90	42	14	-34	-41	6.97E-8	1.93E-6	> 1.00E-4
K-562	0.238	2.355	2.381	2.329	2.056	0.221	0.244	101	99	86	-7	.	2.42E-6	.	> 1.00E-4
MOLT-4	0.828	3.163	3.149	3.088	2.733	0.754	0.567	99	97	82	-9	-32	2.23E-6	7.97E-6	> 1.00E-4
RPMI-8226	0.917	2.740	2.812	2.801	2.464	0.522	0.464	104	103	85	-43	-49	1.87E-6	4.60E-6	> 1.00E-4
SR	0.473	1.889	1.714	1.660	1.372	0.304	0.266	88	84	64	-36	-44	1.37E-6	4.36E-6	> 1.00E-4
Non-Small Cell Lung Cancer															
A549/ATCC	0.366	1.943	1.869	1.834	1.735	0.257	0.096	95	93	87	-30	-74	2.07E-6	5.54E-6	2.86E-5
EKVX	0.604	1.707	1.723	1.640	1.480	0.213	0.017	101	94	79	-65	-97	1.60E-6	3.56E-6	7.90E-6
HOP-62	0.565	1.899	1.874	1.867	1.858	0.534	0.180	98	98	97	-6	-68	2.87E-6	8.82E-6	5.13E-5
HOP-92	0.933	1.483	1.425	1.454	1.424	0.234	0.125	89	95	89	-75	-87	1.73E-6	3.50E-6	7.05E-6
NCI-H226	0.696	1.723	1.688	1.640	1.621	0.670	0.409	97	92	90	-4	-41	2.68E-6	9.12E-6	> 1.00E-4
NCI-H23	0.477	1.511	1.476	1.538	1.546	0.173	0.132	97	103	103	-64	-72	2.09E-6	4.15E-6	8.27E-6
NCI-H322M	0.541	1.345	1.494	1.454	1.214	0.176	-0.019	118	114	84	-67	-100	1.67E-6	3.58E-6	7.66E-6
NCI-H460	0.190	2.110	2.179	2.206	1.978	0.117	0.056	104	105	93	-39	-71	2.12E-6	5.09E-6	2.27E-5
NCI-H522	0.838	2.285	2.162	2.127	2.092	0.511	0.333	91	89	87	-39	-60	1.96E-6	4.89E-6	3.28E-5
Colon Cancer															
COLO 205	0.428	1.411	1.453	1.509	1.503	0.122	0.127	104	110	109	-71	-70	2.13E-6	4.02E-6	7.60E-6
HCC-2998	0.527	1.355	1.415	1.410	1.488	0.052	0.061	107	107	116	-90	-88	2.09E-6	3.65E-6	6.39E-6
HCT-116	0.198	1.926	1.867	1.801	1.532	0.079	0.022	97	93	77	-60	-89	1.58E-6	3.65E-6	8.44E-6
HCT-15	0.223	1.307	1.334	1.369	1.154	0.098	0.048	102	106	86	-56	-78	1.79E-6	4.02E-6	9.03E-6
HT29	0.241	1.664	1.792	1.731	1.684	0.124	0.085	109	105	101	-49	-65	2.20E-6	4.75E-6	1.23E-5
KM12	0.392	1.972	1.931	1.987	1.827	0.131	0.042	97	101	91	-67	-89	1.82E-6	3.77E-6	7.83E-6
SW-620	0.198	1.628	1.664	1.662	1.610	0.136	0.063	103	102	99	-32	-68	2.37E-6	5.72E-6	3.19E-5
CNS Cancer															
SF-268	0.436	1.598	1.566	1.570	1.477	0.188	0.049	97	98	90	-57	-89	1.86E-6	4.09E-6	8.97E-6
SF-295	0.596	2.048	1.931	1.984	2.087	0.401	0.030	92	96	103	-33	-95	2.45E-6	5.73E-6	1.89E-5
SF-539	0.789	2.524	2.538	2.388	2.366	0.094	0.056	101	92	91	-88	-93	1.69E-6	3.22E-6	6.13E-6
SNB-19	0.461	2.007	1.937	1.993	1.939	0.164	0.021	95	99	96	-64	-96	1.93E-6	3.96E-6	8.13E-6
SNB-75	0.687	1.386	1.318	1.345	1.285	0.182	0.052	90	94	86	-74	-92	1.67E-6	3.45E-6	7.12E-6
U251	0.399	1.818	1.798	1.813	1.773	0.015	-0.007	99	100	97	-96	-100	1.75E-6	3.17E-6	5.76E-6
Melanoma															
LOX IMVI	0.263	1.527	1.598	1.617	1.405	0.025	0.040	106	107	90	-91	-85	1.67E-6	3.15E-6	5.96E-6
MALME-3M	0.606	1.517	1.449	1.508	1.412	0.246	0.100	92	99	88	-59	-84	1.82E-6	3.96E-6	8.63E-6
M14	0.400	1.852	1.855	1.834	1.761	0.220	0.108	100	99	94	-45	-73	2.07E-6	4.74E-6	1.51E-5
MDA-MB-435	0.371	1.840	1.781	1.874	1.809	0.245	0.166	96	102	98	-34	-55	2.31E-6	5.53E-6	5.60E-5
SK-MEL-2	0.886	1.647	1.663	1.668	1.684	0.424	0.151	102	103	105	-52	-83	2.23E-6	4.65E-6	9.69E-6
SK-MEL-28	0.518	1.498	1.516	1.566	1.556	0.080	-0.005	102	107	106	-85	-100	1.96E-6	3.59E-6	6.58E-6
SK-MEL-5	0.744	2.786	2.712	2.769	2.526	0.112	0.061	96	99	87	-85	-92	1.65E-6	3.21E-6	6.27E-6
UACC-257	1.090	2.325	2.247	2.288	2.218	0.474	0.088	94	97	91	-57	-92	1.90E-6	4.15E-6	9.04E-6
UACC-62	0.645	2.439	2.385	2.408	2.239	0.160	0.027	97	98	89	-75	-96	1.73E-6	3.48E-6	7.02E-6
Ovarian Cancer															
IGROV1	0.287	1.174	1.161	1.155	1.026	0.136	0.116	98	98	83	-53	-60	1.76E-6	4.10E-6	9.57E-6
OVCAR-3	0.363	1.494	1.585	1.511	1.434	0.008	-0.014	108	101	95	-98	-100	1.71E-6	3.10E-6	5.64E-6
OVCAR-4	0.514	1.255	1.229	1.290	1.155	0.570	0.045	96	105	86	7	-91	2.90E-6	1.19E-5	3.82E-5
OVCAR-5	0.497	1.591	1.649	1.635	1.523	0.338	0.125	105	104	94	-32	-75	2.23E-6	5.57E-6	2.63E-5
OVCAR-8	0.426	1.907	1.922	1.979	1.714	0.306	0.035	101	105	87	-28	-92	2.09E-6	5.68E-6	2.20E-5
NCI/ADR-RES	0.400	1.274	1.304	1.347	1.259	0.211	0.127	103	108	98	-47	-68	2.15E-6	4.73E-6	1.33E-5
SK-OV-3	0.902	1.930	1.914	1.966	1.967	0.772	0.093	98	104	104	-14	-90	2.84E-6	7.54E-6	2.97E-5
Renal Cancer															
786-0	0.435	2.000	2.007	1.968	1.912	0.097	0.047	100	98	94	-78	-89	1.81E-6	3.53E-6	6.90E-6
A498	1.079	1.874	1.824	1.898	1.825	0.055	0.020	94	103	94	-95	-98	1.71E-6	3.14E-6	5.78E-6
ACHN	0.359	1.610	1.638	1.655	1.540	0.481	-0.028	102	104	94	10	-100	3.35E-6	1.23E-5	3.50E-5
CAKI-1	0.449	1.658	1.577	1.582	1.480	0.388	0.004	93	94	85	-14	-99	2.27E-6	7.29E-6	2.66E-5
RXF 393	0.506	1.219	1.306	1.294	1.165	0.057	0.061	112	111	92	-89	-88	1.72E-6	3.24E-6	6.11E-6
SN12C	0.375	1.501	1.406	1.463	1.414	0.074	0.013	92	97	92	-80	-97	1.76E-6	3.42E-6	6.67E-6
TK-10	0.543	1.369	1.317	1.342	1.397	0.412	0.056	94	97	103	-24	-90	2.62E-6	6.47E-6	2.48E-5
UO-31	0.604	1.769	1.707	1.622	1.357	0.470	-0.014	95	87	65	-22	-100	1.47E-6	5.55E-6	2.28E-5
Prostate Cancer															
PC-3	0.449	1.870	1.807	1.835	1.675	0.154	0.034	96	98	86	-66	-93	1.73E-6	3.70E-6	7.88E-6
DU-145	0.285	1.376	1.385	1.368	1.274	0.015	-0.020	101	99	91	-95	-100	1.66E-6	3.08E-6	5.73E-6
Breast Cancer															
MCF7	0.276	1.456	1.363	1.415	1.210	0.203	0.071	92	97	79	-26	-74	1.89E-6	5.62E-6	3.09E-5
MDA-MB-231/ATCC	0.430	1.397	1.475	1.436	1.356	0.395	0.304	108	104	96	-8	-29	2.76E-6	8.33E-6	> 1.00E-4
HS 578T	1.060	2.202	2.093	2.139	1.971	1.007	0.736	90	94	80	-5	-31	2.24E-6	8.73E-6	> 1.00E-4
BT-549	1.325	2.695	2.630	2.603	2.514	0.438	0.237	95	93	87	-67	-82	1.73E-6	3.67E-6	7.76E-6
T-47D	0.732	1.409	1.383	1.389	1.342	0.574	0.643	96	97	90	-22	-12	2.28E-6	6.40E-6	> 1.00E-4
MDA-MB-468	0.593	1.326	1.280	1.383	1.213	0.280	0.240	94	108	85	-53	-60	1.79E-6	4.13E-6	9.53E-6

National Cancer Institute Developmental Therapeutics Program		NSC : D - 803357/1	Units :Molar	SSPL :0X0S	EXP. ID :1802NS38	
Mean Graphs		Report Date :March 08, 2018		Test Date :February 12, 2018		
Panel/Cell Line	Log ₁₀ GI50	GI50	Log ₁₀ TGI	TGI	Log ₁₀ LC50	LC50
Leukemia						
CCRF-CEM	-5.57		-4.96		> -4.00	
HL-60(TB)	-7.16		-5.72		> -4.00	
K-562	-5.62				> -4.00	
MOLT-4	-5.65		-5.10		> -4.00	
RPMI-8226	-5.73		-5.34		> -4.00	
SR	-5.86		-5.36		> -4.00	
Non-Small Cell Lung Cancer						
A549/ATCC	-5.68		-5.26		-4.54	
EKVX	-5.80		-5.45		-5.10	
HOP-62	-5.54		-5.05		-4.29	
HOP-92	-5.76		-5.46		-5.15	
NCI-H226	-5.57		-5.04		> -4.00	
NCI-H23	-5.68		-5.38		-5.08	
NCI-H322M	-5.78		-5.45		-5.12	
NCI-H460	-5.67		-5.29		-4.64	
NCI-H522	-5.71		-5.31		-4.48	
Colon Cancer						
COLO 205	-5.67		-5.40		-5.12	
HCC-2998	-5.68		-5.44		-5.19	
HCT-116	-5.80		-5.44		-5.07	
HCT-15	-5.75		-5.40		-5.04	
HT29	-5.66		-5.32		-4.91	
KM12	-5.74		-5.42		-5.11	
SW-620	-5.63		-5.24		-4.50	
CNS Cancer						
SF-268	-5.73		-5.39		-5.05	
SF-295	-5.61		-5.24		-4.72	
SF-539	-5.77		-5.49		-5.21	
SNB-19	-5.72		-5.40		-5.09	
SNB-75	-5.78		-5.46		-5.15	
U251	-5.76		-5.50		-5.24	
Melanoma						
LOX IMVI	-5.78		-5.50		-5.22	
MALME-3M	-5.74		-5.40		-5.06	
M14	-5.68		-5.32		-4.82	
MDA-MB-435	-5.64		-5.26		-4.25	
SK-MEL-2	-5.65		-5.33		-5.01	
SK-MEL-28	-5.71		-5.44		-5.18	
SK-MEL-5	-5.78		-5.49		-5.20	
UACC-257	-5.72		-5.38		-5.04	
UACC-62	-5.76		-5.46		-5.15	
Ovarian Cancer						
IGROV1	-5.75		-5.39		-5.02	
OVCAR-3	-5.77		-5.51		-5.25	
OVCAR-4	-5.54		-4.92		-4.42	
OVCAR-5	-5.65		-5.25		-4.58	
OVCAR-8	-5.68		-5.25		-4.66	
NCI/ADR-RES	-5.67		-5.33		-4.88	
SK-OV-3	-5.55		-5.12		-4.53	
Renal Cancer						
786-0	-5.74		-5.45		-5.16	
A498	-5.77		-5.50		-5.24	
ACHN	-5.48		-4.91		-4.46	
CAKI-1	-5.64		-5.14		-4.57	
RXF 393	-5.77		-5.49		-5.21	
SN12C	-5.76		-5.47		-5.18	
TK-10	-5.58		-5.19		-4.61	
UO-31	-5.83		-5.26		-4.64	
Prostate Cancer						
PC-3	-5.76		-5.43		-5.10	
DU-145	-5.78		-5.51		-5.24	
Breast Cancer						


All Cell Lines

Percentage Growth




Log₁₀ of Sample Concentration (Molar)

Leukemia




CCRF-CEM —○— HL-60(TB) ---◇--- K-562 ---△---
MOLT-4 ---□--- RPMI-8226 ---●--- SR ---◆---

Non-Small Cell Lung Cancer




A549/ATCC —○— EKVX ---◇--- HOP-62 ---△---
HOP-92 ---□--- NCI-H226 ---●--- NCI-H23 ---◆---
NCI-H322M ---▲--- NCI-H460 ---■--- NCI-H522 ---○---

Colon Cancer




COLO 205 —○— HCC-2998 ---◇--- HCT-116 ---△---
HCT-15 ---□--- HT29 ---●--- KM12 ---◆---
SW-620 ---▲---

CNS Cancer




SF-268 —○— SF-295 ---◇--- SF-539 ---△---
SNB-19 ---□--- SNB-75 ---●--- U251 ---◆---

Melanoma




LOX IMVI —○— MALME-3M ---◇--- M14 ---△---
MDA-MB-435 ---□--- SK-MEL-2 ---●--- SK-MEL-28 ---◆---
SK-MEL-5 ---▲--- UACC-257 ---■--- UACC-62 ---○---

Ovarian Cancer




IGROV1 —○— OVCAR-3 ---◇--- OVCAR-4 ---△---
OVCAR-5 ---□--- OVCAR-8 ---●--- NCI/ADR-RES ---◆---
SK-OV-3 ---▲---

Renal Cancer




786-0 —○— A498 ---◇--- ACHN ---△---
CAKI-1 ---□--- RXF 393 ---●--- SN12C ---◆---
TK-10 ---▲--- UO-31 ---■---

Prostate Cancer



PC-3 —○— DU-145 ---◇---

Breast Cancer



MCF7 —○— MDA-MB-231 ---◇--- HS 578T ---△---
BT-549 ---□--- T-47D ---●--- MDA-MB-468 ---◆---

National Cancer Institute Developmental Therapeutics Program
In-Vitro Testing Results


NSC : D - 803361 / 1	Experiment ID : 1802NS38	Test Type : 08	Units : Molar
Report Date : March 08, 2018	Test Date : February 12, 2018	QNS :	MC :
COMI : CC-35	Stain Reagent : SRB Dual-Pass Related	SSPL : 0X0S	

Panel/Cell Line	Log10 Concentration												GI50	TGI	LC50
	Time Zero	Ctrl	-8.0	-7.0	-6.0	-5.0	-4.0	-8.0	-7.0	-6.0	-5.0	-4.0			
Leukemia															
CCRF-CEM	0.459	2.832	2.721	2.706	1.771	0.454	0.430	95	95	55	-1	-6	1.24E-6	9.56E-6	> 1.00E-4
HL-60(TB)	0.772	2.616	2.467	2.435	2.069	0.528	0.592	92	90	70	-32	-23	1.58E-6	4.89E-6	> 1.00E-4
K-562	0.238	2.322	2.294	2.313	1.795	0.283	0.191	99	100	75	2	-20	2.19E-6	1.25E-5	> 1.00E-4
MOLT-4	0.828	3.039	3.030	2.967	2.605	0.740	0.571	100	97	80	-11	-31	2.16E-6	7.63E-6	> 1.00E-4
RPMI-8226	0.917	2.710	2.652	2.615	1.876	0.622	0.546	97	95	53	-32	-40	1.10E-6	4.21E-6	> 1.00E-4
SR	0.473	1.912	1.750	1.643	1.297	0.388	0.356	89	81	57	-18	-25	1.25E-6	5.77E-6	> 1.00E-4
Non-Small Cell Lung Cancer															
A549/ATCC	0.366	1.950	1.862	1.954	1.982	0.371	0.102	94	100	102	.	-72	3.25E-6	1.01E-5	4.93E-5
EKVX	0.604	1.739	1.604	1.690	1.693	0.650	0.051	88	96	96	4	-92	3.16E-6	1.10E-5	3.67E-5
HOP-62	0.565	1.850	1.819	1.910	1.881	0.459	0.040	98	105	102	-19	-93	2.70E-6	6.99E-6	2.63E-5
HOP-92	0.933	1.578	1.459	1.506	1.441	0.550	0.049	82	89	79	-41	-95	1.74E-6	4.54E-6	1.46E-5
NCI-H226	0.696	1.806	1.762	1.743	1.774	0.692	0.189	96	94	97	.	-73	3.03E-6	9.85E-6	4.82E-5
NCI-H23	0.477	1.372	1.443	1.330	1.383	0.254	0.157	108	95	101	-47	-67	2.22E-6	4.83E-6	1.44E-5
NCI-H322M	0.541	1.424	1.501	1.346	1.307	0.616	0.008	109	91	87	8	-99	2.95E-6	1.20E-5	3.51E-5
NCI-H460	0.190	2.111	2.159	2.138	1.861	0.080	0.033	103	101	87	-58	-83	1.80E-6	3.98E-6	8.82E-6
NCI-H522	0.838	2.263	2.232	2.198	2.165	0.260	0.074	98	95	93	-69	-91	1.84E-6	3.75E-6	7.64E-6
Colon Cancer															
COLO 205	0.428	1.419	1.463	1.431	1.484	0.414	0.104	104	101	107	-3	-76	3.27E-6	9.32E-6	4.40E-5
HCC-2998	0.527	1.501	1.350	1.240	1.431	0.122	0.043	84	73	93	-77	-92	1.79E-6	3.52E-6	6.94E-6
HCT-116	0.198	1.774	1.636	1.700	1.502	0.076	0.010	91	95	83	-62	-95	1.69E-6	3.74E-6	8.31E-6
HCT-15	0.223	1.262	1.388	1.309	1.166	0.150	0.068	112	104	91	-33	-70	2.14E-6	5.43E-6	2.95E-5
HT29	0.241	1.690	1.619	1.690	1.715	0.138	0.102	95	100	102	-43	-58	2.28E-6	5.06E-6	3.02E-5
KM12	0.392	1.915	1.984	1.931	1.853	0.285	0.033	105	101	96	-27	-92	2.36E-6	5.99E-6	2.25E-5
SW-620	0.198	1.571	1.641	1.506	1.523	0.167	0.073	105	95	96	-16	-63	2.59E-6	7.22E-6	5.27E-5
CNS Cancer															
SF-268	0.436	1.590	1.557	1.560	1.490	0.419	0.031	97	97	91	-4	-93	2.72E-6	9.10E-6	3.29E-5
SF-295	0.596	2.007	1.871	1.937	1.976	0.687	0.053	90	95	98	6	-91	3.33E-6	1.16E-5	3.78E-5
SF-539	0.789	2.366	2.416	2.328	2.366	0.304	0.022	103	98	100	-62	-97	2.04E-6	4.16E-6	8.48E-6
SNB-19	0.461	1.847	1.766	1.784	1.784	0.285	0.003	94	95	95	-38	-99	2.19E-6	5.17E-6	1.56E-5
SNB-75	0.687	1.386	1.361	1.277	1.367	0.751	0.006	96	84	97	9	-99	3.44E-6	1.22E-5	3.52E-5
U251	0.399	1.957	1.879	1.922	1.883	0.185	-0.010	95	98	95	-54	-100	2.01E-6	4.36E-6	9.44E-6
Melanoma															
LOX IMVI	0.263	1.494	1.323	1.476	1.408	0.083	0.056	86	99	93	-69	-79	1.85E-6	3.76E-6	7.67E-6
MALME-3M	0.606	1.533	1.548	1.433	1.446	0.492	0.039	102	89	91	-19	-94	2.35E-6	6.72E-6	2.61E-5
M14	0.400	1.798	1.654	1.742	1.726	0.449	0.118	90	96	95	4	-71	3.10E-6	1.12E-5	5.28E-5
MDA-MB-435	0.371	1.770	1.749	1.716	1.726	0.262	0.058	99	96	97	-30	-84	2.35E-6	5.84E-6	2.36E-5
SK-MEL-2	0.886	1.544	1.579	1.607	1.579	0.378	0.053	105	110	105	-57	-94	2.19E-6	4.44E-6	9.01E-6
SK-MEL-28	0.518	1.410	1.466	1.432	1.521	0.237	0.007	106	103	113	-54	-99	2.37E-6	4.73E-6	9.43E-6
SK-MEL-5	0.744	2.770	2.787	2.731	2.700	0.071	0.009	101	98	97	-90	-99	1.77E-6	3.28E-6	6.08E-6
UACC-257	1.090	2.443	2.419	2.482	2.427	1.402	0.050	98	103	99	23	-95	4.40E-6	1.56E-5	4.14E-5
UACC-62	0.645	2.311	2.246	2.166	2.257	0.365	0.033	96	91	97	-43	-95	2.16E-6	4.90E-6	1.34E-5
Ovarian Cancer															
IGROV1	0.287	1.117	1.307	1.131	1.145	0.284	0.083	123	102	103	-1	-71	3.24E-6	9.74E-6	4.97E-5
OVCAR-3	0.363	1.489	1.473	1.489	1.524	0.247	-0.007	99	100	103	-32	-100	2.47E-6	5.80E-6	1.84E-5
OVCAR-4	0.514	1.234	1.179	1.207	1.179	0.613	0.040	92	96	92	14	-92	3.45E-6	1.35E-5	4.00E-5
OVCAR-5	0.497	1.461	1.485	1.441	1.432	0.523	0.078	102	98	97	3	-84	3.15E-6	1.07E-5	4.03E-5
OVCAR-8	0.426	1.944	1.919	1.927	1.841	0.513	0.203	98	99	93	6	-52	3.12E-6	1.25E-5	9.11E-5
NCI/ADR-RES	0.400	1.327	1.375	1.265	1.268	0.311	0.174	105	93	94	-22	-57	2.38E-6	6.41E-6	6.45E-5
SK-OV-3	0.902	1.941	1.908	1.957	2.025	1.024	0.029	97	102	108	12	-97	4.01E-6	1.28E-5	3.70E-5
Renal Cancer															
786-0	0.435	2.049	1.905	1.961	2.052	0.481	0.077	91	95	100	3	-82	3.28E-6	1.08E-5	4.17E-5
A498	1.079	1.887	1.863	1.896	1.871	0.785	0.005	97	101	98	-27	-100	2.42E-6	6.06E-6	2.06E-5
ACHN	0.359	1.480	1.470	1.488	1.494	0.468	-0.008	99	101	101	10	-100	3.63E-6	1.23E-5	3.50E-5
CAKI-1	0.449	1.530	1.458	1.523	1.466	0.635	0.003	93	99	94	17	-99	3.74E-6	1.40E-5	3.77E-5
RXF 393	0.506	1.173	1.225	1.154	1.132	0.105	0.035	108	97	94	-79	-93	1.79E-6	3.48E-6	6.78E-6
SN12C	0.375	1.468	1.483	1.389	1.434	0.421	0.099	101	93	97	4	-74	3.21E-6	1.13E-5	4.97E-5
TK-10	0.543	1.343	1.270	1.347	1.433	0.572	0.025	91	100	111	4	-95	3.70E-6	1.09E-5	3.48E-5
UO-31	0.604	1.774	1.542	1.556	1.562	0.533	0.005	80	81	82	-12	-99	2.19E-6	7.49E-6	2.74E-5
Prostate Cancer															
PC-3	0.449	1.935	1.770	1.750	1.582	0.302	0.060	89	88	76	-33	-87	1.74E-6	5.00E-6	2.08E-5
DU-145	0.285	1.316	1.282	1.333	1.189	0.371	-0.010	97	102	88	8	-100	2.98E-6	1.19E-5	3.46E-5
Breast Cancer															
MCF7	0.276	1.363	1.357	1.281	1.127	0.353	0.103	99	92	78	7	-63	2.49E-6	1.26E-5	6.58E-5
MDA-MB-231/ATCC	0.430	1.386	1.460	1.482	1.400	0.560	0.176	108	110	101	14	-59	3.85E-6	1.54E-5	7.48E-5
HS 578T	1.060	2.181	2.098	2.099	2.170	1.284	0.831	93	93	99	20	-22	4.17E-6	3.02E-5	> 1.00E-4
BT-549	1.325	2.537	2.431	2.464	2.602	1.129	0.194	91	94	105	-15	-85	2.89E-6	7.53E-6	3.15E-5
T-47D	0.732	1.455	1.383	1.419	1.444	0.789	0.602	90	95	98	8	-18	3.43E-6	2.03E-5	> 1.00E-4
MDA-MB-468	0.593	1.284	1.348	1.220	1.278	0.333	0.167	109	91	99	-44	-72	2.20E-6	4.93E-6	1.66E-5

National Cancer Institute Developmental Therapeutics Program		NSC : D - 803361/1	Units :Molar	SSPL :0X0S	EXP. ID :1802NS38
Mean Graphs		Report Date :March 08, 2018		Test Date :February 12, 2018	
Panel/Cell Line	Log ₁₀ GI50 GI50	Log ₁₀ TGI TGI	Log ₁₀ LC50 LC50		
Leukemia					
CCRF-CEM	-5.91	-5.02	> -4.00		
HL-60(TB)	-5.80	-5.31	> -4.00		
K-562	-5.66	-4.90	> -4.00		
MOLT-4	-5.67	-5.12	> -4.00		
RPMI-8226	-5.96	-5.38	> -4.00		
SR	-5.90	-5.24	> -4.00		
Non-Small Cell Lung Cancer					
A549/ATCC	-5.49	-5.00	-4.31		
EKVX	-5.50	-4.96	-4.43		
HOP-62	-5.57	-5.16	-4.58		
HOP-92	-5.76	-5.34	-4.83		
NCI-H226	-5.52	-5.01	-4.32		
NCI-H23	-5.65	-5.32	-4.84		
NCI-H322M	-5.53	-4.92	-4.45		
NCI-H460	-5.74	-5.40	-5.05		
NCI-H522	-5.73	-5.43	-5.12		
Colon Cancer					
COLO 205	-5.49	-5.03	-4.36		
HCC-2998	-5.75	-5.45	-5.16		
HCT-116	-5.77	-5.43	-5.08		
HCT-15	-5.67	-5.27	-4.53		
HT29	-5.64	-5.30	-4.52		
KM12	-5.63	-5.22	-4.65		
SW-620	-5.59	-5.14	-4.28		
CNS Cancer					
SF-268	-5.57	-5.04	-4.48		
SF-295	-5.48	-4.93	-4.42		
SF-539	-5.69	-5.38	-5.07		
SNB-19	-5.66	-5.29	-4.81		
SNB-75	-5.46	-4.92	-4.45		
U251	-5.70	-5.36	-5.03		
Melanoma					
LOX IMVI	-5.73	-5.42	-5.12		
MALME-3M	-5.63	-5.17	-4.58		
M14	-5.51	-4.95	-4.28		
MDA-MB-435	-5.63	-5.23	-4.63		
SK-MEL-2	-5.66	-5.35	-5.05		
SK-MEL-28	-5.63	-5.33	-5.03		
SK-MEL-5	-5.75	-5.48	-5.22		
UACC-257	-5.36	-4.81	-4.38		
UACC-62	-5.67	-5.31	-4.87		
Ovarian Cancer					
IGROV1	-5.49	-5.01	-4.30		
OVCAR-3	-5.61	-5.24	-4.73		
OVCAR-4	-5.46	-4.87	-4.40		
OVCAR-5	-5.50	-4.97	-4.39		
OVCAR-8	-5.51	-4.90	-4.04		
NCI/ADR-RES	-5.62	-5.19	-4.19		
SK-OV-3	-5.40	-4.89	-4.43		
Renal Cancer					
786-0	-5.48	-4.97	-4.38		
A498	-5.62	-5.22	-4.69		
ACHN	-5.44	-4.91	-4.46		
CAKI-1	-5.43	-4.85	-4.42		
RXF 393	-5.75	-5.46	-5.17		
SN12C	-5.49	-4.95	-4.30		
TK-10	-5.43	-4.96	-4.46		
UO-31	-5.66	-5.13	-4.56		
Prostate Cancer					
PC-3	-5.76	-5.30	-4.68		
DU-145	-5.53	-4.92	-4.46		
Breast Cancer					
MCF7	-5.60	-4.90	-4.18		
MDA-MB-231/ATCC	-5.41	-4.81	-4.13		
HS 578T	-5.38	-4.52	> -4.00		
BT-549	-5.54	-5.12	> -4.00		
T-47D	-5.47	-4.69	> -4.00		
MDA-MB-468	-5.66	-5.31	-4.78		
MID	-5.6	-5.12	-4.53		
Delta	0.36	0.36	0.69		
Range	0.6	0.96	1.22		

All Cell Lines


Percentage Growth




S803361

Log₁₀ of Sample Concentration (Molar)


Leukemia




Non-Small Cell Lung Cancer




Colon Cancer




CNS Cancer




Melanoma




Ovarian Cancer




Renal Cancer



Prostate Cancer




Breast Cancer



National Cancer Institute Developmental Therapeutics Program
In-Vitro Testing Results


NSC : D - 803358 / 1	Experiment ID : 1802NS38	Test Type : 08	Units : Molar
Report Date : March 08, 2018	Test Date : February 12, 2018	QNS :	MC :
COMI : CC-51	Stain Reagent : SRB Dual-Pass Related	SSPL : 0X0S	

Panel/Cell Line	Log10 Concentration														
	Time Zero	Ctrl	-8.0	-7.0	-6.0	-5.0	-4.0	-8.0	-7.0	-6.0	-5.0	-4.0	GI50	TGI	LC50
Leukemia															
CCRF-CEM	0.459	2.705	2.667	2.708	2.397	0.427	0.332	98	100	86	-7	-28	2.45E-6	8.42E-6	> 1.00E-4
HL-60(TB)	0.772	2.424	1.857	1.087	1.190	0.364	0.276	66	19	25	-53	-64	2.17E-8	2.10E-6	> 9.18E-6
K-562	0.238	2.388	2.224	2.130	1.629	0.165	0.216	92	88	65	-31	-9	1.42E-6	4.75E-6	> 1.00E-4
MOLT-4	0.828	3.083	3.104	2.571	1.638	0.483	0.429	101	77	36	-42	-48	4.57E-7	2.90E-6	> 1.00E-4
RPMI-8226	0.917	2.665	2.711	2.722	2.215	0.539	0.549	103	103	74	-41	-40	1.62E-6	4.39E-6	> 1.00E-4
SR	0.473	1.572	1.171	1.219	0.788	0.228	0.249	64	68	29	-52	-47	2.85E-7	2.27E-6	.
Non-Small Cell Lung Cancer															
A549/ATCC	0.366	1.754	1.692	1.741	1.623	0.306	0.101	95	99	91	-17	-73	2.39E-6	7.01E-6	3.96E-5
EKVX	0.604	1.819	1.779	1.737	1.548	0.350	0.063	97	93	78	-42	-90	1.70E-6	4.45E-6	1.46E-5
HOP-62	0.565	1.859	1.858	1.891	1.819	0.483	0.095	100	102	97	-15	-83	2.63E-6	7.40E-6	3.28E-5
HOP-92	0.933	1.443	1.413	1.363	1.336	0.329	0.111	94	84	79	-65	-88	1.59E-6	3.55E-6	7.90E-6
NCI-H226	0.696	1.751	1.616	1.740	1.652	0.682	0.370	87	99	91	-2	-47	2.74E-6	9.51E-6	> 1.00E-4
NCI-H23	0.477	1.488	1.525	1.458	1.384	0.182	0.122	104	97	90	-62	-75	1.83E-6	3.91E-6	8.35E-6
NCI-H322M	0.541	1.409	1.408	1.376	1.255	0.023	0.005	100	96	82	-96	-99	1.52E-6	2.90E-6	5.53E-6
NCI-H460	0.190	1.909	1.984	1.976	1.722	0.119	0.088	104	104	89	-38	-54	2.03E-6	5.05E-6	5.90E-5
NCI-H522	0.838	2.249	2.186	2.149	2.182	0.492	0.195	95	93	95	-41	-77	2.14E-6	4.98E-6	1.76E-5
Colon Cancer															
COLO 205	0.428	1.367	1.458	1.404	1.439	0.158	0.116	110	104	108	-63	-73	2.18E-6	4.27E-6	8.37E-6
HCC-2998	0.527	1.516	1.506	1.550	1.386	0.054	0.045	99	103	87	-90	-92	1.62E-6	3.10E-6	5.95E-6
HCT-116	0.198	1.837	1.762	1.770	1.510	0.059	0.021	95	96	80	-70	-90	1.58E-6	3.41E-6	7.34E-6
HCT-15	0.223	1.254	1.273	1.197	1.023	0.119	0.039	102	94	78	-47	-83	1.66E-6	4.20E-6	1.22E-5
HT29	0.241	1.638	1.728	1.678	1.679	0.143	0.120	106	103	103	-41	-50	2.34E-6	5.21E-6	9.07E-5
KM12	0.392	1.770	1.864	1.830	1.685	0.072	0.024	107	104	94	-82	-94	1.78E-6	3.43E-6	6.60E-6
SW-620	0.198	1.514	1.614	1.505	1.499	0.098	0.052	108	99	99	-51	-74	2.12E-6	4.59E-6	9.92E-6
CNS Cancer															
SF-268	0.436	1.525	1.517	1.473	1.389	0.062	0.032	99	95	87	-86	-93	1.65E-6	3.20E-6	6.22E-6
SF-295	0.596	2.011	1.896	1.943	1.968	0.252	0.033	92	95	97	-58	-95	2.01E-6	4.24E-6	8.91E-6
SF-539	0.789	2.354	2.316	2.355	2.263	0.026	0.017	98	100	94	-97	-98	1.70E-6	3.11E-6	5.69E-6
SNB-19	0.461	1.946	1.865	1.915	1.772	0.057	0.015	95	98	88	-88	-97	1.65E-6	3.18E-6	6.11E-6
SNB-75	0.687	1.400	1.341	1.350	1.202	0.117	0.064	92	93	72	-83	-91	1.39E-6	2.92E-6	6.13E-6
U251	0.399	1.761	1.681	1.704	1.610	0.026	0.010	94	96	89	-94	-98	1.63E-6	3.07E-6	5.77E-6
Melanoma															
LOX IMVI	0.263	1.607	1.649	1.591	1.443	0.046	0.058	103	99	88	-83	-78	1.67E-6	3.28E-6	6.44E-6
MALME-3M	0.606	1.485	1.559	1.482	1.462	0.220	0.044	108	100	97	-64	-93	1.97E-6	4.02E-6	8.21E-6
M14	0.400	1.784	1.798	1.798	1.721	0.143	0.082	101	101	95	-64	-80	1.92E-6	3.96E-6	8.13E-6
MDA-MB-435	0.371	1.719	1.786	1.785	1.668	0.286	0.081	105	105	96	-23	-78	2.44E-6	6.41E-6	3.08E-5
SK-MEL-2	0.886	1.681	1.750	1.698	1.686	0.355	0.136	109	102	101	-60	-85	2.07E-6	4.23E-6	8.67E-6
SK-MEL-28	0.518	1.431	1.435	1.522	1.437	0.058	0.013	100	110	101	-89	-98	1.85E-6	3.39E-6	6.23E-6
SK-MEL-5	0.744	2.672	2.554	2.706	2.561	0.041	0.065	94	102	94	-95	-91	1.72E-6	3.16E-6	5.81E-6
UACC-257	1.090	2.186	2.160	2.180	2.145	0.149	0.056	98	99	96	-86	-95	1.79E-6	3.37E-6	6.32E-6
UACC-62	0.645	2.455	2.318	2.335	2.198	0.177	0.020	92	93	86	-73	-97	1.68E-6	3.48E-6	7.20E-6
Ovarian Cancer															
IGROV1	0.287	1.208	1.192	1.238	1.074	0.214	0.104	98	103	85	-25	-64	2.09E-6	5.90E-6	4.35E-5
OVCAR-3	0.363	1.445	1.460	1.484	1.371	0.023	0.007	101	104	93	-94	-98	1.70E-6	3.15E-6	5.84E-6
OVCAR-4	0.514	1.189	1.258	1.240	1.166	0.584	0.132	110	108	97	10	-74	3.47E-6	1.32E-5	5.16E-5
OVCAR-5	0.497	1.478	1.514	1.509	1.410	0.207	0.030	104	103	93	-58	-94	1.93E-6	4.12E-6	8.81E-6
OVCAR-8	0.426	1.781	1.780	1.752	1.543	0.265	0.109	100	98	82	-38	-75	1.86E-6	4.84E-6	2.14E-5
NCI/ADR-RES	0.400	1.343	1.332	1.360	1.253	0.164	0.141	99	102	90	-59	-65	1.86E-6	4.03E-6	8.71E-6
SK-OV-3	0.902	1.909	1.886	1.937	1.895	0.809	0.089	98	103	99	-10	-90	2.79E-6	8.03E-6	3.14E-5
Renal Cancer															
786-0	0.435	1.988	1.981	1.893	1.927	0.058	0.028	100	94	96	-87	-94	1.79E-6	3.35E-6	6.30E-6
A498	1.079	1.855	1.869	1.812	1.794	0.056	0.029	102	95	92	-95	-97	1.68E-6	3.11E-6	5.76E-6
ACHN	0.359	1.568	1.704	1.678	1.538	0.267	-0.006	111	109	98	-26	-100	2.43E-6	6.18E-6	2.12E-5
CAKI-1	0.449	1.520	1.508	1.502	1.382	0.229	0.018	99	98	87	-49	-96	1.87E-6	4.37E-6	1.05E-5
RXF 393	0.506	1.211	1.315	1.231	1.183	0.055	0.051	115	103	96	-89	-90	1.77E-6	3.30E-6	6.14E-6
SN12C	0.375	1.454	1.453	1.442	1.346	0.060	0.017	100	99	90	-84	-96	1.70E-6	3.29E-6	6.37E-6
TK-10	0.543	1.303	1.275	1.283	1.353	0.406	0.037	96	97	107	-25	-93	2.69E-6	6.43E-6	2.31E-5
UO-31	0.604	1.775	1.628	1.703	1.486	0.059	0.006	87	94	75	-90	-99	1.42E-6	2.85E-6	5.71E-6
Prostate Cancer															
PC-3	0.449	1.868	1.751	1.793	1.663	0.107	0.051	92	95	86	-76	-89	1.66E-6	3.38E-6	6.88E-6
DU-145	0.285	1.248	1.259	1.252	1.149	0.005	0.002	101	100	90	-98	-99	1.63E-6	3.00E-6	5.53E-6
Breast Cancer															
MCF7	0.276	1.469	1.465	1.421	1.178	0.165	0.093	100	96	76	-40	-66	1.66E-6	4.48E-6	2.35E-5
MDA-MB-231/ATCC	0.430	1.379	1.397	1.450	1.367	0.422	0.131	102	107	99	-2	-70	3.05E-6	9.58E-6	5.13E-5
HS 578T	1.060	2.067	2.084	2.017	1.899	0.956	0.691	102	95	83	-10	-35	2.28E-6	7.84E-6	> 1.00E-4
BT-549	1.325	2.636	2.603	2.592	2.472	0.312	0.078	97	97	87	-76	-94	1.69E-6	3.42E-6	6.90E-6
T-47D	0.732	1.380	1.381	1.382	1.311	0.668	0.557	100	100	89	-9	-24	2.52E-6	8.13E-6	> 1.00E-4
MDA-MB-468	0.593	1.263	1.267	1.289	1.246	0.228	0.152	100	104	97	-62	-74	1.99E-6	4.10E-6	8.46E-6



All Cell Lines


Percentage Growth




S803358

Log₁₀ of Sample Concentration (Molar)


Leukemia




Non-Small Cell Lung Cancer




Colon Cancer




CNS Cancer




Melanoma




Ovarian Cancer




Renal Cancer



Prostate Cancer



Breast Cancer



National Cancer Institute Developmental Therapeutics Program
In-Vitro Testing Results


NSC : D - 803363 / 1	Experiment ID : 1802NS38	Test Type : 08	Units : Molar
Report Date : March 08, 2018	Test Date : February 12, 2018	QNS :	MC :
COMI : CC-50	Stain Reagent : SRB Dual-Pass Related	SSPL : 0X0S	

Panel/Cell Line	Log10 Concentration															
	Time Zero	Mean Optical Densities						Percent Growth						GI50	TGI	LC50
	Ctrl	-8.0	-7.0	-6.0	-5.0	-4.0	-8.0	-7.0	-6.0	-5.0	-4.0					
Leukemia																
CCRF-CEM	0.459	2.748	2.752	2.698	2.366	0.438	0.350	100	98	83	-5	-24	2.39E-6	8.87E-6	> 1.00E-4	
HL-60(TB)	0.772	2.524	2.155	2.028	2.045	0.619	0.584	79	72	73	-20	-24	1.76E-6	6.10E-6	> 1.00E-4	
K-562	0.238	2.261	2.344	2.276	1.613	0.291	0.290	104	101	68	3	3	1.88E-6	> 1.00E-4	> 1.00E-4	
MOLT-4	0.828	3.067	3.025	3.020	2.779	0.800	0.521	98	98	87	-3	-37	2.57E-6	9.18E-6	> 1.00E-4	
RPMI-8226	0.917	2.656	2.709	2.685	2.466	0.628	0.520	103	102	89	-32	-43	2.11E-6	5.48E-6	> 1.00E-4	
SR	0.473	1.876	1.665	1.583	1.450	0.422	0.345	85	79	70	-11	-27	1.76E-6	7.34E-6	> 1.00E-4	
Non-Small Cell Lung Cancer																
A549/ATCC	0.366	1.788	1.622	1.687	1.748	1.370	0.030	88	93	97	71	-92	1.34E-5	2.72E-5	5.53E-5	
EKVX	0.604	1.780	1.711	1.645	1.616	1.072	0.091	94	89	86	40	-85	6.02E-6	2.08E-5	5.24E-5	
HOP-62	0.565	1.946	1.902	1.908	1.840	0.457	0.063	97	97	92	-19	-89	2.40E-6	6.73E-6	2.76E-5	
HOP-92	0.933	1.462	1.356	1.413	1.347	0.748	0.021	80	91	78	-20	-98	1.94E-6	6.27E-6	2.44E-5	
NCI-H226	0.696	1.770	1.640	1.771	1.688	0.577	0.155	88	100	92	-17	-78	2.44E-6	6.98E-6	3.48E-5	
NCI-H23	0.477	1.366	1.312	1.447	1.353	0.223	0.063	94	109	99	-53	-87	2.09E-6	4.45E-6	9.50E-6	
NCI-H322M	0.541	1.385	1.440	1.429	1.344	0.566	-0.002	107	105	95	3	-100	3.09E-6	1.07E-5	3.27E-5	
NCI-H460	0.190	2.143	2.119	2.317	2.117	0.101	0.065	99	109	99	-47	-66	2.16E-6	4.76E-6	1.47E-5	
NCI-H522	0.838	2.259	2.093	2.061	1.947	0.351	0.190	88	86	78	-58	-77	1.61E-6	3.74E-6	8.72E-6	
Colon Cancer																
COLO 205	0.428	1.355	1.419	1.431	1.498	0.415	0.132	107	108	115	-3	-69	3.57E-6	9.43E-6	5.13E-5	
HCC-2998	0.527	1.220	1.246	1.152	1.193	0.139	0.035	104	90	96	-74	-93	1.87E-6	3.68E-6	7.26E-6	
HCT-116	0.198	1.763	1.774	1.751	1.335	0.115	0.013	101	99	73	-42	-93	1.58E-6	4.31E-6	1.44E-5	
HCT-15	0.223	1.328	1.279	1.256	0.984	0.119	0.052	96	94	69	-47	-77	1.46E-6	3.94E-6	1.27E-5	
HT29	0.241	1.613	1.634	1.629	1.506	0.115	0.066	102	101	92	-52	-73	1.96E-6	4.35E-6	9.64E-6	
KM12	0.392	2.058	2.038	2.060	1.814	0.208	0.059	99	100	85	-47	-85	1.85E-6	4.42E-6	1.20E-5	
SW-620	0.198	1.642	1.634	1.661	1.479	0.179	0.053	99	101	89	-10	-73	2.47E-6	7.94E-6	4.30E-5	
CNS Cancer																
SF-268	0.436	1.636	1.647	1.606	1.473	0.407	0.061	101	97	86	-7	-86	2.46E-6	8.48E-6	3.52E-5	
SF-295	0.596	2.027	2.039	1.957	1.946	0.518	0.061	101	95	94	-13	-90	2.59E-6	7.54E-6	3.02E-5	
SF-539	0.789	2.593	2.593	2.542	2.310	0.576	0.020	100	97	84	-27	-98	2.03E-6	5.72E-6	2.12E-5	
SNB-19	0.461	2.004	2.019	1.973	1.794	0.403	0.015	101	98	86	-13	-97	2.33E-6	7.46E-6	2.78E-5	
SNB-75	0.687	1.391	1.362	1.329	1.206	0.715	0.008	96	91	74	4	-99	2.19E-6	1.09E-5	3.35E-5	
U251	0.399	1.799	1.796	1.861	1.564	0.098	0.007	100	104	83	-76	-98	1.62E-6	3.34E-6	6.90E-6	
Melanoma																
LOX IMVI	0.263	1.565	1.643	1.491	1.376	0.076	0.045	106	94	85	-71	-83	1.68E-6	3.51E-6	7.31E-6	
MALME-3M	0.606	1.520	1.530	1.483	1.439	0.686	0.052	101	96	91	9	-92	3.16E-6	1.22E-5	3.86E-5	
M14	0.400	1.767	1.753	1.763	1.617	0.353	0.069	99	100	89	-12	-83	2.44E-6	7.65E-6	3.45E-5	
MDA-MB-435	0.371	1.741	1.821	1.683	1.745	0.340	0.022	106	96	100	-8	-94	2.90E-6	8.36E-6	3.05E-5	
SK-MEL-2	0.886	1.528	1.617	1.571	1.551	0.770	0.094	114	107	104	-13	-89	2.88E-6	7.72E-6	3.04E-5	
SK-MEL-28	0.518	1.523	1.519	1.511	1.501	0.257	0.011	100	99	98	-50	-98	2.10E-6	4.57E-6	9.93E-6	
SK-MEL-5	0.744	2.778	2.827	2.584	2.627	0.087	0.060	102	90	93	-88	-92	1.72E-6	3.25E-6	6.14E-6	
UACC-257	1.090	2.137	2.100	2.070	2.038	1.053	0.016	96	94	91	-3	-99	2.70E-6	9.19E-6	3.09E-5	
UACC-62	0.645	2.394	2.347	2.321	2.269	0.227	0.027	97	96	93	-65	-96	1.87E-6	3.88E-6	8.06E-6	
Ovarian Cancer																
IGROV1	0.287	1.198	1.214	1.241	1.070	0.261	0.097	102	105	86	-9	-66	2.39E-6	8.00E-6	5.20E-5	
OVCAR-3	0.363	1.547	1.664	1.666	1.495	0.263	0.012	110	110	96	-28	-97	2.34E-6	5.96E-6	2.10E-5	
OVCAR-4	0.514	1.233	1.200	1.258	1.144	0.508	0.063	95	104	88	-1	-88	2.65E-6	9.70E-6	3.66E-5	
OVCAR-5	0.497	1.610	1.549	1.625	1.452	0.644	0.058	94	101	86	13	-88	3.11E-6	1.35E-5	4.19E-5	
OVCAR-8	0.426	1.798	1.852	1.787	1.607	0.392	0.046	104	99	86	-8	-89	2.41E-6	8.20E-6	3.29E-5	
NCI/ADR-RES	0.400	1.342	1.416	1.275	1.242	0.325	0.188	108	93	89	-19	-53	2.31E-6	6.71E-6	8.11E-5	
SK-OV-3	0.902	1.955	1.893	2.010	1.988	1.638	0.055	94	105	103	70	-94	1.32E-5	2.67E-5	5.39E-5	
Renal Cancer																
786-0	0.435	2.008	1.879	1.896	1.805	0.255	0.023	92	93	87	-41	-95	1.94E-6	4.76E-6	1.45E-5	
A498	1.079	1.915	1.863	1.807	1.900	1.705	0.096	94	87	98	75	-91	1.41E-5	2.83E-5	5.65E-5	
ACHN	0.359	1.581	1.669	1.710	1.556	0.330	-0.009	107	111	98	-8	-100	2.83E-6	8.39E-6	2.86E-5	
CAKI-1	0.449	1.594	1.536	1.502	1.365	0.530	0.002	95	92	80	7	-100	2.58E-6	1.17E-5	3.43E-5	
RXF 393	0.506	1.131	1.227	1.147	1.095	0.057	0.047	115	103	94	-89	-91	1.74E-6	3.27E-6	6.13E-6	
SN12C	0.375	1.557	1.484	1.453	1.309	0.467	0.035	94	91	79	8	-91	2.55E-6	1.20E-5	3.86E-5	
TK-10	0.543	1.300	1.283	1.269	1.256	0.480	0.003	98	96	94	-12	-99	2.61E-6	7.75E-6	2.73E-5	
UO-31	0.604	1.736	1.662	1.655	1.358	0.416	0.023	93	93	67	-31	-96	1.48E-6	4.80E-6	1.95E-5	
Prostate Cancer																
PC-3	0.449	1.768	1.702	1.715	1.552	0.312	0.030	95	96	84	-31	-93	1.97E-6	5.39E-6	2.03E-5	
DU-145	0.285	1.407	1.399	1.357	1.230	0.371	-0.003	99	96	84	8	-100	2.80E-6	1.18E-5	3.43E-5	
Breast Cancer																
MCF7	0.276	1.339	1.355	1.264	1.059	0.344	0.121	101	93	74	6	-56	2.25E-6	1.26E-5	7.92E-5	
MDA-MB-231/ATCC	0.430	1.373	1.437	1.382	1.265	0.532	0.025	107	101	89	11	-94	3.13E-6	1.27E-5	3.79E-5	
HS 578T	1.060	2.193	2.148	2.127	2.042	1.182	0.791	96	94	87	11	-25	3.04E-6	1.98E-5	> 1.00E-4	
BT-549	1.325	2.507	2.441	2.476	2.319	0.998	0.066	94	97	84	-25	-95	2.06E-6	5.93E-6	2.29E-5	
T-47D	0.732	1.442	1.437	1.449	1.342	0.777	0.354	99	101	86	6	-52	2.82E-6	1.29E-5	9.35E-5	
MDA-MB-468	0.593	1.279	1.378	1.233	1.194	0.253	0.139	114	93	88	-57	-77	1.82E-6	4.02E-6	8.89E-6	

National Cancer Institute Developmental Therapeutics Program		NSC : D - 803363/1		Units :Molar		SSPL :0X0S		EXP. ID :1802NS38	
Mean Graphs		Report Date :March 08, 2018				Test Date :February 12, 2018			
Panel/Cell Line	Log ₁₀ GI50	GI50	Log ₁₀ TGI	TGI	Log ₁₀ LC50	LC50			
Leukemia									
CCRF-CEM	-5.62		-5.05		> -4.00				
HL-60(TB)	-5.76		-5.21		> -4.00				
K-562	-5.73		> -4.00		> -4.00				
MOLT-4	-5.59		-5.04		> -4.00				
RPMI-8226	-5.68		-5.26		> -4.00				
SR	-5.76		-5.13		> -4.00				
Non-Small Cell Lung Cancer									
A549/ATCC	-4.87		-4.57		-4.26				
EKVX	-5.22		-4.68		-4.28				
HOP-62	-5.62		-5.17		-4.56				
HOP-92	-5.71		-5.20		-4.61				
NCI-H226	-5.61		-5.16		-4.46				
NCI-H23	-5.68		-5.35		-5.02				
NCI-H322M	-5.51		-4.97		-4.49				
NCI-H460	-5.67		-5.32		-4.83				
NCI-H522	-5.79		-5.43		-5.06				
Colon Cancer									
COLO 205	-5.45		-5.03		-4.29				
HCC-2998	-5.73		-5.43		-5.14				
HCT-116	-5.80		-5.37		-4.84				
HCT-15	-5.84		-5.40		-4.90				
HT29	-5.71		-5.36		-5.02				
KM12	-5.73		-5.35		-4.92				
SW-620	-5.61		-5.10		-4.37				
CNS Cancer									
SF-268	-5.61		-5.07		-4.45				
SF-295	-5.59		-5.12		-4.52				
SF-539	-5.69		-5.24		-4.67				
SNB-19	-5.63		-5.13		-4.56				
SNB-75	-5.66		-4.96		-4.48				
U251	-5.79		-5.48		-5.16				
Melanoma									
LOX IMVI	-5.77		-5.45		-5.14				
MALME-3M	-5.50		-4.91		-4.41				
M14	-5.61		-5.12		-4.46				
MDA-MB-435	-5.54		-5.08		-4.52				
SK-MEL-2	-5.54		-5.11		-4.52				
SK-MEL-28	-5.68		-5.34		-5.00				
SK-MEL-5	-5.76		-5.49		-5.21				
UACC-257	-5.57		-5.04		-4.51				
UACC-62	-5.73		-5.41		-5.09				
Ovarian Cancer									
IGROV1	-5.62		-5.10		-4.28				
OVCAR-3	-5.63		-5.22		-4.68				
OVCAR-4	-5.58		-5.01		-4.44				
OVCAR-5	-5.51		-4.87		-4.38				
OVCAR-8	-5.62		-5.09		-4.48				
NCI/ADR-RES	-5.64		-5.17		-4.09				
SK-OV-3	-4.88		-4.57		-4.27				
Renal Cancer									
786-0	-5.71		-5.32		-4.84				
A498	-4.85		-4.55		-4.25				
ACHN	-5.55		-5.08		-4.54				
CAKI-1	-5.59		-4.93		-4.46				
RXF 393	-5.76		-5.49		-5.21				
SN12C	-5.59		-4.92		-4.41				
TK-10	-5.58		-5.11		-4.56				
UO-31	-5.83		-5.32		-4.71				
Prostate Cancer									
PC-3	-5.71		-5.27		-4.69				
DU-145	-5.55		-4.93		-4.46				
Breast Cancer									
MCF7	-5.65		-4.90		-4.10				
MDA-MB-231/ATCC	-5.50		-4.90		-4.42				
HS 578T	-5.52		-4.70		> -4.00				
BT-549	-5.69		-5.23		-4.64				
T-47D	-5.55		-4.89		-4.03				
MDA-MB-468	-5.74		-5.40		-5.05				

All Cell Lines


Percentage Growth




S803363

Log₁₀ of Sample Concentration (Molar)


Leukemia




Non-Small Cell Lung Cancer




Colon Cancer




CNS Cancer




Melanoma




Ovarian Cancer




Renal Cancer



Prostate Cancer



Breast Cancer



National Cancer Institute Developmental Therapeutics Program
In-Vitro Testing Results


NSC : D - 803355 / 1	Experiment ID : 1802NS38	Test Type : 08	Units : Molar
Report Date : March 08, 2018	Test Date : February 12, 2018	QNS :	MC :
COMI : CC-45	Stain Reagent : SRB Dual-Pass Related	SSPL : 0X0S	

Panel/Cell Line	Log10 Concentration														
	Time Zero	Ctrl	-8.0	-7.0	-6.0	-5.0	-4.0	-8.0	-7.0	-6.0	-5.0	-4.0	GI50	TGI	LC50
Leukemia															
CCRF-CEM	0.459	2.748	2.745	2.697	1.822	0.458	0.441	100	98	60	0	-4	1.44E-6	9.92E-6	> 1.00E-4
HL-60(TB)	0.772	2.524	2.256	2.352	1.664	0.428	0.350	85	90	51	-45	-55	1.02E-6	3.41E-6	3.43E-5
K-562	0.238	2.261	2.274	2.225	1.393	0.350	0.200	101	98	57	6	-16	1.37E-6	1.81E-5	> 1.00E-4
MOLT-4	0.828	3.067	3.049	3.042	2.499	0.816	0.561	99	99	75	-2	-32	2.11E-6	9.55E-6	> 1.00E-4
RPMI-8226	0.917	2.656	2.665	2.640	1.927	0.610	0.533	100	99	58	-34	-42	1.22E-6	4.30E-6	> 1.00E-4
SR	0.473	1.876	1.775	1.696	1.112	0.439	0.347	93	87	46	-7	-27	7.82E-7	7.31E-6	> 1.00E-4
Non-Small Cell Lung Cancer															
A549/ATCC	0.366	1.788	1.753	1.808	1.636	0.302	0.017	98	101	89	-17	-95	2.33E-6	6.86E-6	2.62E-5
EKVX	0.604	1.780	1.534	1.668	1.593	0.379	0.075	79	90	84	-37	-88	1.91E-6	4.93E-6	1.79E-5
HOP-62	0.565	1.946	1.785	1.822	1.700	0.278	0.038	88	91	82	-51	-93	1.75E-6	4.15E-6	9.86E-6
HOP-92	0.933	1.462	1.441	1.430	1.415	0.490	0.025	96	94	91	-48	-97	1.98E-6	4.54E-6	1.12E-5
NCI-H226	0.696	1.770	1.785	1.698	1.662	0.758	0.144	101	93	90	6	-79	2.98E-6	1.17E-5	4.52E-5
NCI-H23	0.477	1.366	1.427	1.309	1.288	0.199	0.083	107	94	91	-58	-83	1.89E-6	4.07E-6	8.79E-6
NCI-H322M	0.541	1.385	1.370	1.358	1.196	0.041	-0.003	98	97	78	-92	-100	1.45E-6	2.86E-6	5.63E-6
NCI-H460	0.190	2.143	2.247	2.191	1.227	0.127	0.035	105	102	53	-33	-82	1.09E-6	4.11E-6	2.21E-5
NCI-H522	0.838	2.259	2.184	2.131	1.921	0.266	0.067	95	91	76	-68	-92	1.52E-6	3.37E-6	7.47E-6
Colon Cancer															
COLO 205	0.428	1.355	1.381	1.420	1.335	0.098	0.046	103	107	98	-77	-89	1.88E-6	3.62E-6	7.00E-6
HCC-2998	0.527	1.220	1.239	1.100	1.226	0.083	0.060	103	83	101	-84	-89	1.88E-6	3.51E-6	6.53E-6
HCT-116	0.198	1.763	1.710	1.602	1.329	0.054	0.022	97	90	72	-73	-89	1.42E-6	3.14E-6	6.95E-6
HCT-15	0.223	1.328	1.312	1.248	0.857	0.108	0.013	99	93	57	-52	-94	1.17E-6	3.35E-6	9.63E-6
HT29	0.241	1.613	1.504	1.598	1.400	0.136	0.048	92	99	84	-44	-80	1.86E-6	4.56E-6	1.48E-5
KM12	0.392	2.058	2.041	1.915	1.627	0.079	0.039	99	91	74	-80	-90	1.43E-6	3.03E-6	6.39E-6
SW-620	0.198	1.642	1.575	1.518	1.270	0.136	0.053	95	91	74	-32	-73	1.69E-6	5.03E-6	2.75E-5
CNS Cancer															
SF-268	0.436	1.636	1.552	1.567	1.321	0.254	0.017	93	94	74	-42	-96	1.61E-6	4.35E-6	1.42E-5
SF-295	0.596	2.027	1.925	1.890	1.755	0.189	0.031	93	90	81	-68	-95	1.61E-6	3.49E-6	7.53E-6
SF-539	0.789	2.593	2.515	2.449	2.467	0.424	0.028	96	92	93	-46	-96	2.04E-6	4.65E-6	1.19E-5
SNB-19	0.461	2.004	1.985	1.877	1.672	0.110	0.013	99	92	78	-76	-97	1.53E-6	3.22E-6	6.77E-6
SNB-75	0.687	1.391	1.268	1.277	1.227	0.387	0.006	83	84	77	-44	-99	1.67E-6	4.34E-6	1.30E-5
U251	0.399	1.799	1.745	1.788	1.448	0.015	0.005	96	99	75	-96	-99	1.40E-6	2.74E-6	5.37E-6
Melanoma															
LOX IMVI	0.263	1.565	1.367	1.472	1.000	0.039	0.069	85	93	57	-85	-74	1.11E-6	2.51E-6	5.65E-6
MALME-3M	0.606	1.520	1.527	1.515	1.468	0.365	0.056	101	99	94	-40	-91	2.14E-6	5.05E-6	1.58E-5
M14	0.400	1.767	1.734	1.761	1.590	0.182	0.068	98	100	87	-55	-83	1.83E-6	4.12E-6	9.29E-6
MDA-MB-435	0.371	1.741	1.672	1.757	1.423	0.256	0.018	95	101	77	-31	-95	1.77E-6	5.15E-6	1.97E-5
SK-MEL-2	0.886	1.528	1.528	1.573	1.431	0.378	0.048	100	107	85	-57	-95	1.76E-6	3.95E-6	8.88E-6
SK-MEL-28	0.518	1.523	1.566	1.533	1.571	0.136	0.003	104	101	105	-74	-99	2.03E-6	3.86E-6	7.35E-6
SK-MEL-5	0.744	2.778	2.801	2.734	2.607	0.076	0.053	101	98	92	-90	-93	1.69E-6	3.20E-6	6.03E-6
UACC-257	1.090	2.137	2.100	2.145	2.135	0.205	0.009	96	101	100	-81	-99	1.88E-6	3.56E-6	6.72E-6
UACC-62	0.645	2.394	2.335	2.350	2.168	0.063	0.001	97	97	87	-90	-100	1.62E-6	3.10E-6	5.93E-6
Ovarian Cancer															
IGROV1	0.287	1.198	1.268	1.209	0.831	0.248	0.105	108	101	60	-14	-64	1.36E-6	6.52E-6	5.35E-5
OVCAR-3	0.363	1.547	1.604	1.565	1.279	0.034	0.004	105	101	77	-91	-99	1.45E-6	2.88E-6	5.72E-6
OVCAR-4	0.514	1.233	1.178	1.234	1.108	0.562	0.037	92	100	83	7	-93	2.69E-6	1.17E-5	3.71E-5
OVCAR-5	0.497	1.610	1.631	1.529	1.552	0.251	0.047	102	93	95	-49	-91	2.04E-6	4.54E-6	1.03E-5
OVCAR-8	0.426	1.798	1.754	1.762	1.471	0.314	0.067	97	97	76	-26	-84	1.80E-6	5.54E-6	2.56E-5
NCI/ADR-RES	0.400	1.342	1.323	1.310	1.253	0.402	0.261	98	97	91	0	-35	2.81E-6	1.01E-5	> 1.00E-4
SK-OV-3	0.902	1.955	1.891	1.892	1.798	0.835	0.007	94	94	85	-7	-99	2.40E-6	8.31E-6	2.91E-5
Renal Cancer															
786-0	0.435	2.008	1.857	1.886	1.742	0.196	0.029	90	92	83	-55	-93	1.74E-6	4.00E-6	9.21E-6
A498	1.079	1.915	1.883	1.910	1.825	0.108	0.009	96	99	89	-90	-99	1.65E-6	3.15E-6	5.98E-6
ACHN	0.359	1.581	1.636	1.538	1.475	0.375	-0.008	104	97	91	1	-100	2.88E-6	1.03E-5	3.21E-5
CAKI-1	0.449	1.594	1.454	1.495	1.320	0.258	-0.001	88	91	76	-43	-100	1.66E-6	4.38E-6	1.35E-5
RXF 393	0.506	1.131	1.185	1.119	1.044	0.061	0.040	109	98	86	-88	-92	1.61E-6	3.12E-6	6.05E-6
SN12C	0.375	1.557	1.487	1.448	1.243	0.138	0.017	94	91	73	-63	-95	1.48E-6	3.44E-6	7.99E-6
TK-10	0.543	1.300	1.233	1.300	1.320	0.332	0.011	91	100	103	-39	-98	2.35E-6	5.31E-6	1.54E-5
UO-31	0.604	1.736	1.613	1.573	1.382	0.072	-0.003	89	86	69	-88	-100	1.32E-6	2.74E-6	5.72E-6
Prostate Cancer															
PC-3	0.449	1.768	1.703	1.642	1.455	0.264	0.057	95	90	76	-41	-87	1.67E-6	4.46E-6	1.55E-5
DU-145	0.285	1.407	1.359	1.320	0.858	0.009	-0.005	96	92	51	-97	-100	1.02E-6	2.21E-6	4.81E-6
Breast Cancer															
MCF7	0.276	1.339	1.336	1.243	0.663	0.117	0.116	100	91	36	-58	-58	5.62E-7	2.43E-6	8.27E-6
MDA-MB-231/ATCC	0.430	1.373	1.358	1.321	1.074	0.270	0.007	98	94	68	-37	-98	1.49E-6	4.44E-6	1.62E-5
HS 578T	1.060	2.193	2.057	2.136	2.017	1.245	0.755	88	95	84	16	-29	3.20E-6	2.30E-5	> 1.00E-4
BT-549	1.325	2.507	2.329	2.417	2.414	0.392	0.033	85	92	92	-70	-98	1.82E-6	3.69E-6	7.49E-6
T-47D	0.732	1.442	1.329	1.367	1.264	0.520	0.312	84	89	75	-29	-57	1.73E-6	5.26E-6	5.48E-5
MDA-MB-468	0.593	1.279	1.183	1.255	1.152	0.278	0.206	86	97	81	-53	-65	1.71E-6	4.03E-6	9.48E-6

National Cancer Institute Developmental Therapeutics Program		NSC : D - 803355/1	Units :Molar	SSPL :0X0S	EXP. ID :1802NS38
Mean Graphs		Report Date :March 08, 2018		Test Date :February 12, 2018	
Panel/Cell Line	Log ₁₀ GI50 GI50	Log ₁₀ TGI TGI	Log ₁₀ LC50 LC50		
Leukemia					
CCRF-CEM	-5.84	-5.00	> -4.00		
HL-60(TB)	-5.99	-5.47	-4.46		
K-562	-5.86	-4.74	> -4.00		
MOLT-4	-5.68	-5.02	> -4.00		
RPMI-8226	-5.91	-5.37	> -4.00		
SR	-6.11	-5.14	> -4.00		
Non-Small Cell Lung Cancer					
A549/ATCC	-5.63	-5.16	-4.58		
EKVX	-5.72	-5.31	-4.75		
HOP-62	-5.76	-5.38	-5.01		
HOP-92	-5.70	-5.34	-4.95		
NCI-H226	-5.53	-4.93	-4.35		
NCI-H23	-5.72	-5.39	-5.06		
NCI-H322M	-5.84	-5.54	-5.25		
NCI-H460	-5.96	-5.39	-4.66		
NCI-H522	-5.82	-5.47	-5.13		
Colon Cancer					
COLO 205	-5.73	-5.44	-5.15		
HCC-2998	-5.72	-5.45	-5.18		
HCT-116	-5.85	-5.50	-5.16		
HCT-15	-5.93	-5.47	-5.02		
HT29	-5.73	-5.34	-4.83		
KM12	-5.84	-5.52	-5.19		
SW-620	-5.77	-5.30	-4.56		
CNS Cancer					
SF-268	-5.79	-5.36	-4.85		
SF-295	-5.79	-5.46	-5.12		
SF-539	-5.69	-5.33	-4.93		
SNB-19	-5.82	-5.49	-5.17		
SNB-75	-5.78	-5.36	-4.89		
U251	-5.85	-5.56	-5.27		
Melanoma					
LOX IMVI	-5.95	-5.60	-5.25		
MALME-3M	-5.67	-5.30	-4.80		
M14	-5.74	-5.38	-5.03		
MDA-MB-435	-5.75	-5.29	-4.71		
SK-MEL-2	-5.75	-5.40	-5.05		
SK-MEL-28	-5.69	-5.41	-5.13		
SK-MEL-5	-5.77	-5.50	-5.22		
UACC-257	-5.72	-5.45	-5.17		
UACC-62	-5.79	-5.51	-5.23		
Ovarian Cancer					
IGROV1	-5.87	-5.19	-4.27		
OVCAR-3	-5.84	-5.54	-5.24		
OVCAR-4	-5.57	-4.93	-4.43		
OVCAR-5	-5.69	-5.34	-4.99		
OVCAR-8	-5.74	-5.26	-4.59		
NCI/ADR-RES	-5.55	-5.00	> -4.00		
SK-OV-3	-5.62	-5.08	-4.54		
Renal Cancer					
786-0	-5.76	-5.40	-5.04		
A498	-5.78	-5.50	-5.22		
ACHN	-5.54	-4.99	-4.49		
CAKI-1	-5.78	-5.36	-4.87		
RXF 393	-5.79	-5.51	-5.22		
SN12C	-5.83	-5.46	-5.10		
TK-10	-5.63	-5.28	-4.81		
UO-31	-5.88	-5.56	-5.24		
Prostate Cancer					
PC-3	-5.78	-5.35	-4.81		
DU-145	-5.99	-5.66	-5.32		
Breast Cancer					
MCF7	-6.25	-5.61	-5.08		
MDA-MB-231/ATCC	-5.83	-5.35	-4.79		
HS 578T	-5.49	-4.64	> -4.00		
BT-549	-5.74	-5.43	-5.13		
T-47D	-5.76	-5.28	-4.26		
MDA-MB-468	-5.77	-5.39	-5.02		
Summary					
MID	-5.78	-5.34	-4.83		
Delta	0.47	0.32	0.49		
Range	0.76	1.02	1.32		

All Cell Lines


Percentage Growth




S803355

Log₁₀ of Sample Concentration (Molar)


Leukemia




Non-Small Cell Lung Cancer




Colon Cancer




CNS Cancer




Melanoma




Ovarian Cancer




Renal Cancer



Prostate Cancer



Breast Cancer



National Cancer Institute Developmental Therapeutics Program
In-Vitro Testing Results


NSC : D - 803355 / 1	Experiment ID : 1802NS38	Test Type : 08	Units : Molar
Report Date : March 08, 2018	Test Date : February 12, 2018	QNS :	MC :
COMI : CC-45	Stain Reagent : SRB Dual-Pass Related	SSPL : 0X0S	

Panel/Cell Line	Log10 Concentration														
	Time Zero	Ctrl	-8.0	-7.0	-6.0	-5.0	-4.0	-8.0	-7.0	-6.0	-5.0	-4.0	GI50	TGI	LC50
Leukemia															
CCRF-CEM	0.459	2.748	2.745	2.697	1.822	0.458	0.441	100	98	60	.	-4	1.44E-6	9.92E-6	> 1.00E-4
HL-60(TB)	0.772	2.524	2.256	2.352	1.664	0.428	0.350	85	90	51	-45	-55	1.02E-6	3.41E-6	3.43E-5
K-562	0.238	2.261	2.274	2.225	1.393	0.350	0.200	101	98	57	6	-16	1.37E-6	1.81E-5	> 1.00E-4
MOLT-4	0.828	3.067	3.049	3.042	2.499	0.816	0.561	99	99	75	-2	-32	2.11E-6	9.55E-6	> 1.00E-4
RPMI-8226	0.917	2.656	2.665	2.640	1.927	0.610	0.533	100	99	58	-34	-42	1.22E-6	4.30E-6	> 1.00E-4
SR	0.473	1.876	1.775	1.696	1.112	0.439	0.347	93	87	46	-7	-27	7.82E-7	7.31E-6	> 1.00E-4
Non-Small Cell Lung Cancer															
A549/ATCC	0.366	1.788	1.753	1.808	1.636	0.302	0.017	98	101	89	-17	-95	2.33E-6	6.86E-6	2.62E-5
EKVX	0.604	1.780	1.534	1.668	1.593	0.379	0.075	79	90	84	-37	-88	1.91E-6	4.93E-6	1.79E-5
HOP-62	0.565	1.946	1.785	1.822	1.700	0.278	0.038	88	91	82	-51	-93	1.75E-6	4.15E-6	9.86E-6
HOP-92	0.933	1.462	1.441	1.430	1.415	0.490	0.025	96	94	91	-48	-97	1.98E-6	4.54E-6	1.12E-5
NCI-H226	0.696	1.770	1.785	1.698	1.662	0.758	0.144	101	93	90	6	-79	2.98E-6	1.17E-5	4.52E-5
NCI-H23	0.477	1.366	1.427	1.309	1.288	0.199	0.083	107	94	91	-58	-83	1.89E-6	4.07E-6	8.79E-6
NCI-H322M	0.541	1.385	1.370	1.358	1.196	0.041	-0.003	98	97	78	-92	-100	1.45E-6	2.86E-6	5.63E-6
NCI-H460	0.190	2.143	2.247	2.191	1.227	0.127	0.035	105	102	53	-33	-82	1.09E-6	4.11E-6	2.21E-5
NCI-H522	0.838	2.259	2.184	2.131	1.921	0.266	0.067	95	91	76	-68	-92	1.52E-6	3.37E-6	7.47E-6
Colon Cancer															
COLO 205	0.428	1.355	1.381	1.420	1.335	0.098	0.046	103	107	98	-77	-89	1.88E-6	3.62E-6	7.00E-6
HCC-2998	0.527	1.220	1.239	1.100	1.226	0.083	0.060	103	83	101	-84	-89	1.88E-6	3.51E-6	6.53E-6
HCT-116	0.198	1.763	1.710	1.602	1.329	0.054	0.022	97	90	72	-73	-89	1.42E-6	3.14E-6	6.95E-6
HCT-15	0.223	1.328	1.312	1.248	0.857	0.108	0.013	99	93	57	-52	-94	1.17E-6	3.35E-6	9.63E-6
HT29	0.241	1.613	1.504	1.598	1.400	0.136	0.048	92	99	84	-44	-80	1.86E-6	4.56E-6	1.48E-5
KM12	0.392	2.058	2.041	1.915	1.627	0.079	0.039	99	91	74	-80	-90	1.43E-6	3.03E-6	6.39E-6
SW-620	0.198	1.642	1.575	1.518	1.270	0.136	0.053	95	91	74	-32	-73	1.69E-6	5.03E-6	2.75E-5
CNS Cancer															
SF-268	0.436	1.636	1.552	1.567	1.321	0.254	0.017	93	94	74	-42	-96	1.61E-6	4.35E-6	1.42E-5
SF-295	0.596	2.027	1.925	1.890	1.755	0.189	0.031	93	90	81	-68	-95	1.61E-6	3.49E-6	7.53E-6
SF-539	0.789	2.593	2.515	2.449	2.467	0.424	0.028	96	92	93	-46	-96	2.04E-6	4.65E-6	1.19E-5
SNB-19	0.461	2.004	1.985	1.877	1.672	0.110	0.013	99	92	78	-76	-97	1.53E-6	3.22E-6	6.77E-6
SNB-75	0.687	1.391	1.268	1.277	1.227	0.387	0.006	83	84	77	-44	-99	1.67E-6	4.34E-6	1.30E-5
U251	0.399	1.799	1.745	1.788	1.448	0.015	0.005	96	99	75	-96	-99	1.40E-6	2.74E-6	5.37E-6
Melanoma															
LOX IMVI	0.263	1.565	1.367	1.472	1.000	0.039	0.069	85	93	57	-85	-74	1.11E-6	2.51E-6	5.65E-6
MALME-3M	0.606	1.520	1.527	1.515	1.468	0.365	0.056	101	99	94	-40	-91	2.14E-6	5.05E-6	1.58E-5
M14	0.400	1.767	1.734	1.761	1.590	0.182	0.068	98	100	87	-55	-83	1.83E-6	4.12E-6	9.29E-6
MDA-MB-435	0.371	1.741	1.672	1.757	1.423	0.256	0.018	95	101	77	-31	-95	1.77E-6	5.15E-6	1.97E-5
SK-MEL-2	0.886	1.528	1.528	1.573	1.431	0.378	0.048	100	107	85	-57	-95	1.76E-6	3.95E-6	8.88E-6
SK-MEL-28	0.518	1.523	1.566	1.533	1.571	0.136	0.003	104	101	105	-74	-99	2.03E-6	3.86E-6	7.35E-6
SK-MEL-5	0.744	2.778	2.801	2.734	2.607	0.076	0.053	101	98	92	-90	-93	1.69E-6	3.20E-6	6.03E-6
UACC-257	1.090	2.137	2.100	2.145	2.135	0.205	0.009	96	101	100	-81	-99	1.88E-6	3.56E-6	6.72E-6
UACC-62	0.645	2.394	2.335	2.350	2.168	0.063	0.001	97	97	87	-90	-100	1.62E-6	3.10E-6	5.93E-6
Ovarian Cancer															
IGROV1	0.287	1.198	1.268	1.209	0.831	0.248	0.105	108	101	60	-14	-64	1.36E-6	6.52E-6	5.35E-5
OVCAR-3	0.363	1.547	1.604	1.565	1.279	0.034	0.004	105	101	77	-91	-99	1.45E-6	2.88E-6	5.72E-6
OVCAR-4	0.514	1.233	1.178	1.234	1.108	0.562	0.037	92	100	83	7	-93	2.69E-6	1.17E-5	3.71E-5
OVCAR-5	0.497	1.610	1.631	1.529	1.552	0.251	0.047	102	93	95	-49	-91	2.04E-6	4.54E-6	1.03E-5
OVCAR-8	0.426	1.798	1.754	1.762	1.471	0.314	0.067	97	97	76	-26	-84	1.80E-6	5.54E-6	2.56E-5
NCI/ADR-RES	0.400	1.342	1.323	1.310	1.253	0.402	0.261	98	97	91	.	-35	2.81E-6	1.01E-5	> 1.00E-4
SK-OV-3	0.902	1.955	1.891	1.892	1.798	0.835	0.007	94	94	85	-7	-99	2.40E-6	8.31E-6	2.91E-5
Renal Cancer															
786-0	0.435	2.008	1.857	1.886	1.742	0.196	0.029	90	92	83	-55	-93	1.74E-6	4.00E-6	9.21E-6
A498	1.079	1.915	1.883	1.910	1.825	0.108	0.009	96	99	89	-90	-99	1.65E-6	3.15E-6	5.98E-6
ACHN	0.359	1.581	1.636	1.538	1.475	0.375	-0.008	104	97	91	1	-100	2.88E-6	1.03E-5	3.21E-5
CAKI-1	0.449	1.594	1.454	1.495	1.320	0.258	-0.001	88	91	76	-43	-100	1.66E-6	4.38E-6	1.35E-5
RXF 393	0.506	1.131	1.185	1.119	1.044	0.061	0.040	109	98	86	-88	-92	1.61E-6	3.12E-6	6.05E-6
SN12C	0.375	1.557	1.487	1.448	1.243	0.138	0.017	94	91	73	-63	-95	1.48E-6	3.44E-6	7.99E-6
TK-10	0.543	1.300	1.233	1.300	1.320	0.332	0.011	91	100	103	-39	-98	2.35E-6	5.31E-6	1.54E-5
UO-31	0.604	1.736	1.613	1.573	1.382	0.072	-0.003	89	86	69	-88	-100	1.32E-6	2.74E-6	5.72E-6
Prostate Cancer															
PC-3	0.449	1.768	1.703	1.642	1.455	0.264	0.057	95	90	76	-41	-87	1.67E-6	4.46E-6	1.55E-5
DU-145	0.285	1.407	1.359	1.320	0.858	0.009	-0.005	96	92	51	-97	-100	1.02E-6	2.21E-6	4.81E-6
Breast Cancer															
MCF7	0.276	1.339	1.336	1.243	0.663	0.117	0.116	100	91	36	-58	-58	5.62E-7	2.43E-6	8.27E-6
MDA-MB-231/ATCC	0.430	1.373	1.358	1.321	1.074	0.270	0.007	98	94	68	-37	-98	1.49E-6	4.44E-6	1.62E-5
HS 578T	1.060	2.193	2.057	2.136	2.017	1.245	0.755	88	95	84	16	-29	3.20E-6	2.30E-5	> 1.00E-4
BT-549	1.325	2.507	2.329	2.417	2.414	0.392	0.033	85	92	92	-70	-98	1.82E-6	3.69E-6	7.49E-6
T-47D	0.732	1.442	1.329	1.367	1.264	0.520	0.312	84	89	75	-29	-57	1.73E-6	5.26E-6	5.48E-5
MDA-MB-468	0.593	1.279	1.183	1.255	1.152	0.278	0.206	86	97	81	-53	-65	1.71E-6	4.03E-6	9.48E-6

National Cancer Institute Developmental Therapeutics Program		NSC : D - 803355/1	Units :Molar	SSPL :0X0S	EXP. ID :1802NS38
Mean Graphs		Report Date :March 08, 2018		Test Date :February 12, 2018	
Panel/Cell Line	Log ₁₀ GI50 GI50	Log ₁₀ TGI TGI	Log ₁₀ LC50 LC50		
Leukemia					
CCRF-CEM	-5.84	-5.00	> -4.00		
HL-60(TB)	-5.99	-5.47	-4.46		
K-562	-5.86	-4.74	> -4.00		
MOLT-4	-5.68	-5.02	> -4.00		
RPMI-8226	-5.91	-5.37	> -4.00		
SR	-6.11	-5.14	> -4.00		
Non-Small Cell Lung Cancer					
A549/ATCC	-5.63	-5.16	-4.58		
EKVX	-5.72	-5.31	-4.75		
HOP-62	-5.76	-5.38	-5.01		
HOP-92	-5.70	-5.34	-4.95		
NCI-H226	-5.53	-4.93	-4.35		
NCI-H23	-5.72	-5.39	-5.06		
NCI-H322M	-5.84	-5.54	-5.25		
NCI-H460	-5.96	-5.39	-4.66		
NCI-H522	-5.82	-5.47	-5.13		
Colon Cancer					
COLO 205	-5.73	-5.44	-5.15		
HCC-2998	-5.72	-5.45	-5.18		
HCT-116	-5.85	-5.50	-5.16		
HCT-15	-5.93	-5.47	-5.02		
HT29	-5.73	-5.34	-4.83		
KM12	-5.84	-5.52	-5.19		
SW-620	-5.77	-5.30	-4.56		
CNS Cancer					
SF-268	-5.79	-5.36	-4.85		
SF-295	-5.79	-5.46	-5.12		
SF-539	-5.69	-5.33	-4.93		
SNB-19	-5.82	-5.49	-5.17		
SNB-75	-5.78	-5.36	-4.89		
U251	-5.85	-5.56	-5.27		
Melanoma					
LOX IMVI	-5.95	-5.60	-5.25		
MALME-3M	-5.67	-5.30	-4.80		
M14	-5.74	-5.38	-5.03		
MDA-MB-435	-5.75	-5.29	-4.71		
SK-MEL-2	-5.75	-5.40	-5.05		
SK-MEL-28	-5.69	-5.41	-5.13		
SK-MEL-5	-5.77	-5.50	-5.22		
UACC-257	-5.72	-5.45	-5.17		
UACC-62	-5.79	-5.51	-5.23		
Ovarian Cancer					
IGROV1	-5.87	-5.19	-4.27		
OVCAR-3	-5.84	-5.54	-5.24		
OVCAR-4	-5.57	-4.93	-4.43		
OVCAR-5	-5.69	-5.34	-4.99		
OVCAR-8	-5.74	-5.26	-4.59		
NCI/ADR-RES	-5.55	-5.00	> -4.00		
SK-OV-3	-5.62	-5.08	-4.54		
Renal Cancer					
786-0	-5.76	-5.40	-5.04		
A498	-5.78	-5.50	-5.22		
ACHN	-5.54	-4.99	-4.49		
CAKI-1	-5.78	-5.36	-4.87		
RXF 393	-5.79	-5.51	-5.22		
SN12C	-5.83	-5.46	-5.10		
TK-10	-5.63	-5.28	-4.81		
UO-31	-5.88	-5.56	-5.24		
Prostate Cancer					
PC-3	-5.78	-5.35	-4.81		
DU-145	-5.99	-5.66	-5.32		
Breast Cancer					
MCF7	-6.25	-5.61	-5.08		
MDA-MB-231/ATCC	-5.83	-5.35	-4.79		
HS 578T	-5.49	-4.64	> -4.00		
BT-549	-5.74	-5.43	-5.13		
T-47D	-5.76	-5.28	-4.26		
MDA-MB-468	-5.77	-5.39	-5.02		
Summary					
MID	-5.78	-5.34	-4.83		
Delta	0.47	0.32	0.49		
Range	0.76	1.02	1.32		

All Cell Lines


Percentage Growth




S803355

Log₁₀ of Sample Concentration (Molar)


Leukemia




Non-Small Cell Lung Cancer




Colon Cancer




CNS Cancer




Melanoma




Ovarian Cancer




Renal Cancer



Prostate Cancer



Breast Cancer



National Cancer Institute Developmental Therapeutics Program
In-Vitro Testing Results

NSC : D - 803360 / 1	Experiment ID : 1802NS38	Test Type : 08	Units : Molar
Report Date : March 08, 2018	Test Date : February 12, 2018	QNS :	MC :
COMI : CC-37	Stain Reagent : SRB Dual-Pass Related	SSPL : 0X0S	

Panel/Cell Line	Time	Log10 Concentration												GI50	TGI	LC50
		Zero	Ctrl	Mean Optical Densities					Percent Growth							
				-8.0	-7.0	-6.0	-5.0	-4.0	-8.0	-7.0	-6.0	-5.0	-4.0			
Leukemia																
CCRF-CEM	0.459	2.785	2.761	2.782	2.175	0.404	0.305	99	100	74	-12	-34	1.89E-6	7.23E-6	> 1.00E-4	
HL-60(TB)	0.772	2.335	1.909	1.845	1.271	0.348	0.418	73	69	32	-55	-46	3.22E-7	2.33E-6	.	
K-562	0.238	2.360	2.300	2.271	2.027	0.250	0.205	97	96	84	1	-14	2.57E-6	1.09E-5	> 1.00E-4	
MOLT-4	0.828	3.064	3.013	2.990	2.500	0.618	0.486	98	97	75	-25	-41	1.77E-6	5.58E-6	> 1.00E-4	
RPMI-8226	0.917	2.829	2.895	2.887	2.388	0.527	0.578	103	103	77	-43	-37	1.68E-6	4.41E-6	> 1.00E-4	
SR	0.473	1.812	1.707	1.712	1.431	0.307	0.258	92	93	72	-35	-45	1.59E-6	4.68E-6	> 1.00E-4	
Non-Small Cell Lung Cancer																
A549/ATCC	0.366	1.864	1.809	1.788	1.720	0.273	0.078	96	95	90	-25	-79	2.23E-6	6.03E-6	2.89E-5	
EKVX	0.604	1.717	1.663	1.666	1.588	0.276	0.126	95	95	88	-54	-79	1.86E-6	4.16E-6	9.33E-6	
HOP-62	0.565	1.941	1.976	1.929	1.857	0.307	0.173	102	99	94	-46	-69	2.06E-6	4.71E-6	1.52E-5	
HOP-92	0.933	1.528	1.464	1.476	1.383	0.278	0.115	89	91	76	-70	-88	1.50E-6	3.30E-6	7.26E-6	
NCI-H226	0.696	1.814	1.779	1.775	1.672	0.517	0.353	97	96	87	-26	-49	2.14E-6	5.91E-6	> 1.00E-4	
NCI-H23	0.477	1.404	1.404	1.360	1.403	0.176	0.141	100	95	100	-63	-70	2.02E-6	4.10E-6	8.31E-6	
NCI-H322M	0.541	1.338	1.310	1.337	1.279	0.007	0.004	96	100	93	-99	-99	1.67E-6	3.05E-6	5.56E-6	
NCI-H460	0.190	2.164	2.154	2.159	2.018	0.064	0.070	100	100	93	-67	-63	1.85E-6	3.82E-6	7.87E-6	
NCI-H522	0.838	2.311	2.223	2.142	2.127	0.196	0.142	94	88	87	-77	-83	1.69E-6	3.41E-6	6.88E-6	
Colon Cancer																
COLO 205	0.428	1.424	1.462	1.507	1.521	0.149	0.085	104	108	110	-65	-80	2.20E-6	4.24E-6	8.18E-6	
HCC-2998	0.527	1.341	1.417	1.415	1.314	0.081	0.055	109	109	97	-85	-90	1.81E-6	3.41E-6	6.44E-6	
HCT-116	0.198	1.781	1.783	1.696	1.573	0.015	0.017	100	95	87	-92	-92	1.61E-6	3.05E-6	5.80E-6	
HCT-15	0.223	1.334	1.317	1.391	1.185	0.124	0.091	98	105	87	-45	-59	1.90E-6	4.57E-6	2.34E-5	
HT29	0.241	1.713	1.768	1.740	1.636	0.115	0.097	104	102	95	-52	-60	2.02E-6	4.41E-6	9.65E-6	
KM12	0.392	1.964	1.912	1.984	1.844	0.078	0.043	97	101	92	-80	-89	1.76E-6	3.43E-6	6.68E-6	
SW-620	0.198	1.647	1.701	1.665	1.690	0.094	0.068	104	101	103	-53	-66	2.19E-6	4.58E-6	9.60E-6	
CNS Cancer																
SF-268	0.436	1.599	1.595	1.578	1.531	0.082	0.058	100	98	94	-81	-87	1.79E-6	3.44E-6	6.63E-6	
SF-295	0.596	2.091	1.889	2.031	1.952	0.171	0.068	86	96	91	-71	-89	1.78E-6	3.63E-6	7.39E-6	
SF-539	0.789	2.487	2.504	2.429	2.267	0.021	0.013	101	97	87	-97	-98	1.59E-6	2.96E-6	5.53E-6	
SNB-19	0.461	1.911	1.869	1.929	1.742	0.022	0.050	97	101	88	-95	-89	1.62E-6	3.03E-6	5.67E-6	
SNB-75	0.687	1.390	1.293	1.312	1.317	0.044	0.034	86	89	90	-94	-95	1.64E-6	3.08E-6	5.78E-6	
U251	0.399	1.888	1.884	1.883	1.793	0.003	0.009	100	100	94	-99	-98	1.68E-6	3.06E-6	5.55E-6	
Melanoma																
LOX IMVI	0.263	1.434	1.508	1.514	1.423	0.052	0.079	106	107	99	-80	-70	1.88E-6	3.57E-6	6.78E-6	
MALME-3M	0.606	1.484	1.446	1.435	1.437	0.019	0.028	96	94	95	-97	-95	1.71E-6	3.12E-6	5.69E-6	
M14	0.400	1.859	1.857	1.829	1.798	0.085	0.065	100	98	96	-79	-84	1.83E-6	3.54E-6	6.84E-6	
MDA-MB-435	0.371	1.740	1.714	1.766	1.707	0.139	0.054	98	102	98	-63	-86	1.98E-6	4.06E-6	8.34E-6	
SK-MEL-2	0.886	1.648	1.702	1.681	1.644	0.192	0.127	107	104	99	-78	-86	1.90E-6	3.62E-6	6.92E-6	
SK-MEL-28	0.518	1.495	1.507	1.520	1.469	0.043	0.030	101	103	97	-92	-94	1.78E-6	3.27E-6	6.01E-6	
SK-MEL-5	0.744	2.897	2.763	2.759	2.686	0.135	0.087	94	94	90	-82	-88	1.71E-6	3.34E-6	6.53E-6	
UACC-257	1.090	2.385	2.362	2.337	2.276	0.237	0.060	98	96	92	-78	-94	1.76E-6	3.46E-6	6.81E-6	
UACC-62	0.645	2.316	2.302	2.313	2.140	0.075	0.023	99	100	89	-88	-97	1.67E-6	3.18E-6	6.08E-6	
Ovarian Cancer																
IGROV1	0.287	1.096	1.121	1.130	1.046	0.130	0.093	103	104	94	-55	-68	1.97E-6	4.27E-6	9.27E-6	
OVCAR-3	0.363	1.548	1.586	1.595	1.476	0.021	0.011	103	104	94	-94	-97	1.71E-6	3.16E-6	5.82E-6	
OVCAR-4	0.514	1.271	1.233	1.185	1.221	0.169	0.072	95	89	93	-67	-86	1.86E-6	3.82E-6	7.82E-6	
OVCAR-5	0.497	1.580	1.561	1.575	1.489	0.075	0.106	98	99	92	-85	-79	1.72E-6	3.30E-6	6.34E-6	
OVCAR-8	0.426	1.858	1.871	1.856	1.747	0.165	0.142	101	100	92	-61	-67	1.88E-6	3.99E-6	8.43E-6	
NCI/ADR-RES	0.400	1.217	1.316	1.335	1.292	0.192	0.205	112	114	109	-52	-49	2.33E-6	4.75E-6	.	
SK-OV-3	0.902	2.061	2.005	2.011	1.976	0.727	0.171	95	96	93	-19	-81	2.40E-6	6.71E-6	3.14E-5	
Renal Cancer																
786-0	0.435	2.096	1.992	1.986	1.951	0.050	0.054	94	93	91	-89	-88	1.70E-6	3.22E-6	6.11E-6	
A498	1.079	1.940	1.956	1.912	1.942	0.076	0.044	102	97	100	-93	-96	1.82E-6	3.30E-6	5.99E-6	
ACHN	0.359	1.556	1.638	1.547	1.533	0.005	-0.004	107	99	98	-99	-100	1.76E-6	3.15E-6	5.66E-6	
CAKI-1	0.449	1.536	1.427	1.483	1.363	0.048	0.006	90	95	84	-89	-99	1.57E-6	3.05E-6	5.93E-6	
RXF 393	0.506	1.182	1.229	1.203	1.142	0.046	0.068	107	103	94	-91	-87	1.73E-6	3.22E-6	6.00E-6	
SN12C	0.375	1.481	1.448	1.443	1.437	0.039	0.064	97	97	96	-90	-83	1.77E-6	3.29E-6	6.12E-6	
TK-10	0.543	1.365	1.337	1.311	1.389	0.074	0.024	97	93	103	-86	-96	1.90E-6	3.50E-6	6.42E-6	
UO-31	0.604	1.698	1.630	1.580	1.430	0.008	0.004	94	89	76	-99	-99	1.40E-6	2.71E-6	5.25E-6	
Prostate Cancer																
PC-3	0.449	1.965	1.841	1.874	1.692	0.063	0.052	92	94	82	-86	-88	1.55E-6	3.08E-6	6.10E-6	
DU-145	0.285	1.334	1.368	1.384	1.316	0.042	0.007	103	105	98	-85	-98	1.83E-6	3.43E-6	6.42E-6	
Breast Cancer																
MCF7	0.276	1.368	1.295	1.371	1.198	0.106	0.087	93	100	84	-62	-69	1.72E-6	3.79E-6	8.33E-6	
MDA-MB-231/ATCC	0.430	1.384	1.430	1.467	1.338	0.305	0.140	105	109	95	-29	-67	2.31E-6	5.82E-6	3.50E-5	
HS 578T	1.060	2.146	2.134	2.124	2.193	0.859	0.805	99	98	104	-19	-24	2.76E-6	7.01E-6	> 1.00E-4	
BT-549	1.325	2.678	2.598	2.529	2.506	0.236	0.062	94	89	87	-82	-95	1.66E-6	3.27E-6	6.46E-6	
T-47D	0.732	1.491	1.499	1.434	1.367	0.721	0.602	101	92	84	-2	-18	2.48E-6	9.58E-6	> 1.00E-4	
MDA-MB-468	0.593	1.301	1.289	1.322	1.266	0.241	0.148	98	103	95	-59	-75	1.96E-6	4.13E-6	8.70E-6	

National Cancer Institute Developmental Therapeutics Program		NSC : D - 803360/1	Units :Molar	SSPL :0X0S	EXP. ID :1802NS38	
Mean Graphs		Report Date :March 08, 2018		Test Date :February 12, 2018		
Panel/Cell Line	Log ₁₀ GI50	GI50	Log ₁₀ TGI	TGI	Log ₁₀ LC50	LC50
Leukemia						
CCRF-CEM	-5.72		-5.14		> -4.00	
HL-60(TB)	-6.49		-5.63			
K-562	-5.59		-4.96		> -4.00	
MOLT-4	-5.75		-5.25		> -4.00	
RPMI-8226	-5.77		-5.36		> -4.00	
SR	-5.80		-5.33		> -4.00	
Non-Small Cell Lung Cancer						
A549/ATCC	-5.65		-5.22		-4.54	
EKVX	-5.73		-5.38		-5.03	
HOP-62	-5.69		-5.33		-4.82	
HOP-92	-5.82		-5.48		-5.14	
NCI-H226	-5.67		-5.23		> -4.00	
NCI-H23	-5.69		-5.39		-5.08	
NCI-H322M	-5.78		-5.52		-5.25	
NCI-H460	-5.73		-5.42		-5.10	
NCI-H522	-5.77		-5.47		-5.16	
Colon Cancer						
COLO 205	-5.66		-5.37		-5.09	
HCC-2998	-5.74		-5.47		-5.19	
HCT-116	-5.79		-5.52		-5.24	
HCT-15	-5.72		-5.34		-4.63	
HT29	-5.70		-5.36		-5.02	
KM12	-5.75		-5.46		-5.18	
SW-620	-5.66		-5.34		-5.02	
CNS Cancer						
SF-268	-5.75		-5.46		-5.18	
SF-295	-5.75		-5.44		-5.13	
SF-539	-5.80		-5.53		-5.26	
SNB-19	-5.79		-5.52		-5.25	
SNB-75	-5.78		-5.51		-5.24	
U251	-5.77		-5.51		-5.26	
Melanoma						
LOX IMVI	-5.73		-5.45		-5.17	
MALME-3M	-5.77		-5.51		-5.24	
M14	-5.74		-5.45		-5.16	
MDA-MB-435	-5.70		-5.39		-5.08	
SK-MEL-2	-5.72		-5.44		-5.16	
SK-MEL-28	-5.75		-5.49		-5.22	
SK-MEL-5	-5.77		-5.48		-5.19	
UACC-257	-5.76		-5.46		-5.17	
UACC-62	-5.78		-5.50		-5.22	
Ovarian Cancer						
IGROV1	-5.71		-5.37		-5.03	
OVCAR-3	-5.77		-5.50		-5.24	
OVCAR-4	-5.73		-5.42		-5.11	
OVCAR-5	-5.76		-5.48		-5.20	
OVCAR-8	-5.73		-5.40		-5.07	
NCI/ADR-RES	-5.63		-5.32			
SK-OV-3	-5.62		-5.17		-4.50	
Renal Cancer						
786-0	-5.77		-5.49		-5.21	
A498	-5.74		-5.48		-5.22	
ACHN	-5.76		-5.50		-5.25	
CAKI-1	-5.80		-5.52		-5.23	
RXF 393	-5.76		-5.49		-5.22	
SN12C	-5.75		-5.48		-5.21	
TK-10	-5.72		-5.46		-5.19	
UO-31	-5.85		-5.57		-5.28	
Prostate Cancer						
PC-3	-5.81		-5.51		-5.21	
DU-145	-5.74		-5.46		-5.19	
Breast Cancer						
MCF7	-5.76		-5.42		-5.08	
MDA-MB-231/ATCC	-5.64		-5.23		-4.46	
HS 578T	-5.56		-5.15		> -4.00	
BT-549	-5.78		-5.48		-5.19	
T-47D	-5.61		-5.02		> -4.00	
MDA-MB-468	-5.71		-5.38		-5.06	


Dose Response Curves

Report Date:March 08, 2018

Test Date:February 12, 2018

All Cell Lines

Percentage Growth



Log₁₀ of Sample Concentration (Molar)